



## Clinical trial results:

### A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myeloproliferative Neoplasms)

#### Summary

EudraCT number	2018-000579-34
Trial protocol	GB NL BE PL IT
Global end of trial date	09 January 2025

#### Results information

Result version number	v1 (current)
This version publication date	20 November 2025
First version publication date	20 November 2025

#### Trial information

##### Trial identification

Sponsor protocol code	0610-02
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02158858
WHO universal trial number (UTN)	-
Other trial identifiers	Novartis: CDAK539A12201

Notes:

#### Sponsors

Sponsor organisation name	Novartis Pharma AG, on behalf of Constellation Pharmaceuticals
Sponsor organisation address	Lichtstrasse 35, Basel, Switzerland, 4056
Public contact	Clinical Disclosure Office, Novartis Pharma AG, on behalf of Constellation Pharmaceuticals, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, on behalf of Constellation Pharmaceuticals, 41 613241111, Novartis.email@Novartis.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 January 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 January 2025
Global end of trial reached?	Yes
Global end of trial date	09 January 2025
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of Phase 1 (dose escalation) was to determine the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of pelabresib (CPI-0610) in patients with acute leukemia, myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or myelofibrosis (MF). The primary objective of Phase 2 (dose expansion of pelabresib with and without ruxolitinib in patients with MPN) was to evaluate in MF patients splenic response by imaging after 24 weeks of treatment and, for MF patients who were transfusion dependent, to assess the transfusion independence rate. In patients with essential thrombocytopenia (ET) the primary objective was to evaluate the complete hematological response rate of pelabresib monotherapy.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 July 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 17
Country: Number of subjects enrolled	Canada: 29
Country: Number of subjects enrolled	France: 10
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Italy: 55
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Poland: 8
Country: Number of subjects enrolled	United Kingdom: 44
Country: Number of subjects enrolled	United States: 163
Worldwide total number of subjects	336
EEA total number of subjects	100

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	108
From 65 to 84 years	222
85 years and over	6

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 54 centers across 9 countries (Belgium, Canada, France, Germany, Italy, Netherlands, Poland, United Kingdom, United States)

### Pre-assignment

Screening details:

Not completed = Participants who discontinued study treatment

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Phase 1 (24 mg capsule PO daily)

Arm description:

Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Phase 1 (48 mg capsule PO daily)
------------------	----------------------------------

Arm description:

Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Phase 1 (120 mg capsule PO daily)
------------------	-----------------------------------

Arm description:

Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Phase 1 (170 mg capsule PO daily)
------------------	-----------------------------------

**Arm description:**

Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Phase 1 (230 mg capsule PO daily)
------------------	-----------------------------------

**Arm description:**

Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Phase 1 (300 mg capsule PO daily)
------------------	-----------------------------------

**Arm description:**

Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Phase 1 (400 mg capsule PO daily)
Arm description: Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details: Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)	
<b>Arm title</b>	Phase 1 (225 mg tablet PO daily)
Arm description: Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)	
<b>Arm title</b>	Phase 1 (275 mg tablet PO daily)
Arm description: Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)	
<b>Arm title</b>	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A
Arm description: In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Arm type	Experimental

Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B
------------------	---------------------------------------

**Arm description:**

In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Ph2 Arm2 MF JAKi combo – Cohort 2A
------------------	------------------------------------

**Arm description:**

In Phase 2 (Arm 2) – Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

Investigational medicinal product name	Ruxolitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.

<b>Arm title</b>	Ph2 Arm2 MF JAKi combo – Cohort 2B
------------------	------------------------------------

**Arm description:**

In Phase 2 (Arm 2) – Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ruxolitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.

Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Arm title</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx
------------------	-----------------------------------

**Arm description:**

Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

Investigational medicinal product name	Ruxolitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.

<b>Arm title</b>	Ph2 Arm4 ET – Monotherapy
------------------	---------------------------

**Arm description:**

Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.

Arm type	Experimental
Investigational medicinal product name	Pelabresib
Investigational medicinal product code	
Other name	CPI-0610, DAK539
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Pelabresib was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

<b>Number of subjects in period 1</b>	Phase 1 (24 mg capsule PO daily)	Phase 1 (48 mg capsule PO daily)	Phase 1 (120 mg capsule PO daily)
Started	3	5	5
Completed	0	0	0
Not completed	3	5	5
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	1	1	1
Physician decision	-	-	-
Disease progression	1	3	3
Adverse event, non-fatal	-	1	1
Transitioned to pelabresib extension study	-	-	-
Other protocol defined stopping criteria	1	-	-
Cell transplant	-	-	-

<b>Number of subjects in period 1</b>	Phase 1 (170 mg capsule PO daily)	Phase 1 (230 mg capsule PO daily)	Phase 1 (300 mg capsule PO daily)
Started	3	3	4
Completed	0	0	0
Not completed	3	3	4
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	-	-	-
Physician decision	-	-	-
Disease progression	2	3	2
Adverse event, non-fatal	1	-	2
Transitioned to pelabresib extension study	-	-	-
Other protocol defined stopping criteria	-	-	-
Cell transplant	-	-	-

<b>Number of subjects in period 1</b>	Phase 1 (400 mg capsule PO daily)	Phase 1 (225 mg tablet PO daily)	Phase 1 (275 mg tablet PO daily)
Started	7	8	6
Completed	0	0	0
Not completed	7	8	6
Adverse event, serious fatal	-	1	1
Consent withdrawn by subject	1	3	2

Physician decision	1	-	2
Disease progression	3	1	-
Adverse event, non-fatal	1	3	1
Transitioned to pelabresib extension study	-	-	-
Other protocol defined stopping criteria	1	-	-
Cell transplant	-	-	-

Number of subjects in period 1	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A
Started	48	52	59
Completed	0	0	0
Not completed	48	52	59
Adverse event, serious fatal	4	3	4
Consent withdrawn by subject	5	8	6
Physician decision	20	13	14
Disease progression	5	9	13
Adverse event, non-fatal	10	7	17
Transitioned to pelabresib extension study	2	7	3
Other protocol defined stopping criteria	2	1	-
Cell transplant	-	4	2

Number of subjects in period 1	Ph2 Arm2 MF JAKi combo – Cohort 2B	Ph2 Arm3 MF JAKi- naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy
Started	28	84	21
Completed	0	0	0
Not completed	28	84	21
Adverse event, serious fatal	1	8	-
Consent withdrawn by subject	3	10	4
Physician decision	6	10	3
Disease progression	7	12	1
Adverse event, non-fatal	6	14	4
Transitioned to pelabresib extension study	-	14	9
Other protocol defined stopping criteria	2	3	-
Cell transplant	3	13	-

## Baseline characteristics

### Reporting groups

Reporting group title	Phase 1 (24 mg capsule PO daily)
Reporting group description: Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (48 mg capsule PO daily)
Reporting group description: Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (120 mg capsule PO daily)
Reporting group description: Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (170 mg capsule PO daily)
Reporting group description: Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (230 mg capsule PO daily)
Reporting group description: Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (300 mg capsule PO daily)
Reporting group description: Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (400 mg capsule PO daily)
Reporting group description: Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (225 mg tablet PO daily)
Reporting group description: Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (275 mg tablet PO daily)
Reporting group description: Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A

Reporting group description:

In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B
-----------------------	---------------------------------------

Reporting group description:

In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm2 MF JAKi combo – Cohort 2A
-----------------------	------------------------------------

Reporting group description:

In Phase 2 (Arm 2) – Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm2 MF JAKi combo – Cohort 2B
-----------------------	------------------------------------

Reporting group description:

In Phase 2 (Arm 2) – Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm3 MF JAKi-naïve – Combo Tx
-----------------------	-----------------------------------

Reporting group description:

Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm4 ET – Monotherapy
-----------------------	---------------------------

Reporting group description:

Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.

Reporting group values	Phase 1 (24 mg capsule PO daily)	Phase 1 (48 mg capsule PO daily)	Phase 1 (120 mg capsule PO daily)
Number of subjects	3	5	5
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	1	2	2
From 65-84 years	2	3	3
85 years and over	0	0	0

Age Continuous Units: Years median full range (min-max)	79.0 37 to 79	65.0 55 to 76	69.0 34 to 80
Sex: Female, Male Units: Participants			
Female	3	1	1
Male	0	4	4
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	3	4	4
More than one race	0	0	0
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Phase 1 (170 mg capsule PO daily)	Phase 1 (230 mg capsule PO daily)	Phase 1 (300 mg capsule PO daily)
Number of subjects	3	3	4
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	1	2
From 65-84 years	3	2	2
85 years and over	0	0	0
Age Continuous Units: Years median full range (min-max)	76.0 69 to 79	80.0 57 to 82	66.5 27 to 76
Sex: Female, Male Units: Participants			
Female	3	1	0
Male	0	2	4
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	3	3	1
More than one race	0	0	2
Unknown or Not Reported	0	0	0

Reporting group values	Phase 1 (400 mg capsule PO daily)	Phase 1 (225 mg tablet PO daily)	Phase 1 (275 mg tablet PO daily)
Number of subjects	7	8	6
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	4	4	3
From 65-84 years	3	4	3
85 years and over	0	0	0
Age Continuous Units: Years			
median	63.0	65.5	61.0
full range (min-max)	59 to 77	54 to 82	18 to 80
Sex: Female, Male Units: Participants			
Female	2	1	2
Male	5	7	4
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	0	2
White	6	8	4
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Reporting group values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A
Number of subjects	48	52	59
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	8	15	11
From 65-84 years	37	35	48
85 years and over	3	2	0

Age Continuous Units: Years median full range (min-max)	73.0 60 to 88	69.5 43 to 85	72.0 41 to 83
Sex: Female, Male Units: Participants			
Female Male	16 32	29 23	18 41
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported	0 1 0 4 42 1 0	0 1 0 1 47 2 1	0 1 0 2 54 1 1

<b>Reporting group values</b>	Ph2 Arm2 MF JAKi combo – Cohort 2B	Ph2 Arm3 MF JAKi- naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy
Number of subjects	28	84	21
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over	0 0 0 0 0 0 13 15 0	0 0 0 0 0 0 31 52 1	0 0 0 0 0 0 11 10 0
Age Continuous Units: Years median full range (min-max)	65.5 49 to 78	68.0 37 to 85	64.0 42 to 83
Sex: Female, Male Units: Participants			
Female Male	13 15	25 59	13 8
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported	0 1 0 4 22 1 0	0 3 0 3 75 3 0	0 0 0 0 19 2 0

<b>Reporting group values</b>	Total		
Number of subjects	336		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	108		
From 65-84 years	222		
85 years and over	6		
Age Continuous			
Units: Years			
median			
full range (min-max)	-		
Sex: Female, Male			
Units: Participants			
Female	128		
Male	208		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	8		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	19		
White	295		
More than one race	12		
Unknown or Not Reported	2		

## End points

### End points reporting groups

Reporting group title	Phase 1 (24 mg capsule PO daily)
Reporting group description: Phase 1 (24 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (48 mg capsule PO daily)
Reporting group description: Phase 1 (48 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (120 mg capsule PO daily)
Reporting group description: Phase 1 (120 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (170 mg capsule PO daily)
Reporting group description: Phase 1 (170 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (230 mg capsule PO daily)
Reporting group description: Phase 1 (230 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (300 mg capsule PO daily)
Reporting group description: Phase 1 (300 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (400 mg capsule PO daily)
Reporting group description: Phase 1 (400 mg capsule PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (225 mg tablet PO daily)
Reporting group description: Phase 1 (225 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Phase 1 (275 mg tablet PO daily)
Reporting group description: Phase 1 (275 mg tablet PO daily): Eligible participants in Phase I were enrolled in sequential cohorts based on diagnosis and received escalating doses of pelabresib (CPI-0610) once daily for 14 days, followed by a 7-day break in each 21-day cycle. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.	
Reporting group title	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A

Reporting group description:

In Phase 2 (Arm 1) - Cohort 1A, eligible transfusion-dependent (TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B
-----------------------	---------------------------------------

Reporting group description:

In Phase 2 (Arm 1) - Cohort 1B, eligible non-transfusion-dependent (non-TD) participants received Pelabresib 125 mg QD (tablet) for 14 days, then 7-day break (21-day cycle). Upward titration allowed up to 225 mg QD based on platelet count, hemoglobin, and safety. Treatment stopped upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm2 MF JAKi combo – Cohort 2A
-----------------------	------------------------------------

Reporting group description:

In Phase 2 (Arm 2) – Cohort 2A, eligible transfusion-dependent (TD) participants already on ruxolitinib received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), alongside their stable dose of ruxolitinib. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm2 MF JAKi combo – Cohort 2B
-----------------------	------------------------------------

Reporting group description:

In Phase 2 (Arm 2) – Cohort 2B, eligible non-transfusion-dependent (non-TD) participants already receiving ruxolitinib were treated with Pelabresib 125 mg once daily for 14 days, followed by a 7-day break (21-day cycle), alongside their stable ruxolitinib dose. Pelabresib could be titrated up to 225 mg daily. Treatment was discontinued upon disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm3 MF JAKi-naïve – Combo Tx
-----------------------	-----------------------------------

Reporting group description:

Eligible participants in Phase 2 (Arm 3) received Pelabresib 125 mg once daily for 14 days followed by a 7-day break (21-day cycle), combined with Ruxolitinib, initiated at one dose level below the recommended amount based on baseline platelet count. Dose escalation: a) Ruxolitinib: Required increase of 5 mg twice daily at Cycle 3 Day 1 if criteria were met, up to 25 mg twice daily; b) Pelabresib: Optional increase from Cycle 5 Day 1 in 25 mg steps, no more than once every two cycles, up to 175 mg once daily. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.

Reporting group title	Ph2 Arm4 ET – Monotherapy
-----------------------	---------------------------

Reporting group description:

Eligible participants in Phase 2 (Arm 4) received Pelabresib 225 mg once daily (tablet) was administered for 14 days followed by a 7-day break (21-day cycle). No dose increases beyond 225 mg once daily were permitted. Treatment was discontinued in cases of disease progression, unacceptable toxicity, or pregnancy.

## Primary: Phase 1: Frequency of Dose-limiting toxicities (DLTs)

End point title	Phase 1: Frequency of Dose-limiting toxicities (DLTs) <sup>[1][2]</sup>
-----------------	---

End point description:

A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed by the Investigator as unrelated to disease progression, intercurrent illness, or concomitant medications that occurred within the first cycle of treatment (21-day cycle) with pelabresib (CPI-0610), and that met any of the criteria specified in the protocol.

End point type	Primary
----------------	---------

End point timeframe:

Up to 21 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Endpoint only applicable to Phase I

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase I

End point values	Phase 1 (24 mg capsule PO daily)	Phase 1 (48 mg capsule PO daily)	Phase 1 (120 mg capsule PO daily)	Phase 1 (170 mg capsule PO daily)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	5	3
Units: Participants	0	0	0	0

End point values	Phase 1 (230 mg capsule PO daily)	Phase 1 (300 mg capsule PO daily)	Phase 1 (400 mg capsule PO daily)	Phase 1 (225 mg tablet PO daily)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	6	6
Units: Participants	0	0	1	2

End point values	Phase 1 (275 mg tablet PO daily)			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: Participants	4			

## Statistical analyses

No statistical analyses for this end point

## Primary: Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants with Splenic Response Rate (SVR35) at week 24

End point title	Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants with Splenic Response Rate (SVR35) at week 24 <sup>[3][4]</sup>
-----------------	---

End point description:

Splenic Response Rate (SVR35) at Week 24 was defined as the proportion of participants who demonstrated a reduction of at least 35% in spleen size from baseline, as measured by imaging techniques (MRI or CT), following 24 weeks of treatment.

End point type	Primary
----------------	---------

End point timeframe:

Week 24 (Cycle 9 Day 1)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Endpoint only applicable to Phase II (Cohort 1B, 2B and Arm 3)

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1B, 2B and Arm 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2B	Ph2 Arm3 MF JAKi-naïve – Combo Tx	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	28	84	
Units: Percentage of Participants				
number (confidence interval 95%)	19.2 (9.6 to 32.5)	21.4 (8.3 to 41.0)	67.9 (56.8 to 77.6)	

## Statistical analyses

No statistical analyses for this end point

### Primary: Phase 2 (Cohorts 1A and 2A): Number of Participants enrolled as Transfusion Dependent (TD) with Conversion rate from Red Blood Cell (RBC) transfusion dependence (TD) to transfusion independence (TI)

End point title	Phase 2 (Cohorts 1A and 2A): Number of Participants enrolled as Transfusion Dependent (TD) with Conversion rate from Red Blood Cell (RBC) transfusion dependence (TD) to transfusion independence (TI) <sup>[5][6]</sup>
-----------------	--

End point description:

Conversion rate was defined as the proportion of participants who converted from transfusion dependence (TD) to transfusion independence (TI). TD was characterized by receiving an average of at least 2 units of red blood cell (RBC) transfusions per month—amounting to a minimum of 6 units over the 12 weeks prior to enrollment—while TI was defined as the absence of RBC transfusions during any consecutive 12-week period.

End point type	Primary
----------------	---------

End point timeframe:

12 consecutive weeks (rolling window) up to 7 days following the last dose of pelabresib (CPI-0610)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Endpoint only applicable to Phase II (Cohort 1A and 2A)

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1A and 2A)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm2 MF JAKi combo – Cohort 2A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	59		
Units: Percentage of Participants				
number (confidence interval 95%)	25.6 (13.5 to 41.2)	26.1 (14.3 to 41.1)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Phase 2 (Arm 4): Number of Participants with Complete Hematological Response (CHR) Rate

End point title	Phase 2 (Arm 4): Number of Participants with Complete Hematological Response (CHR) Rate <sup>[7][8]</sup>
End point description: Complete Hematological Response (CHR) Rate was defined as the proportion of participants who fulfilled the criteria for CHR, based on the modified European LeukemiaNet (ELN) guidelines (Barosi et al 2009): platelet count $\leq 400 \times 10^9/L$ , white blood cell (WBC) count $\leq 10 \times 10^9/L$ , confirmation of laboratory values after one treatment cycle, and normal spleen size determined by palpation or imaging.	
End point type	Primary
End point timeframe: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)	

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Endpoint only applicable to Phase II (Arm 4)

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 4)

<b>End point values</b>	Ph2 Arm4 ET – Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Percentage of Participants				
number (confidence interval 95%)	57.1 (34.0 to 78.2)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1: Number of adverse events and serious adverse events as assessed by CTCAE criteria

End point title	Phase 1: Number of adverse events and serious adverse events as assessed by CTCAE criteria <sup>[9]</sup>
End point description: The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).	
End point type	Secondary
End point timeframe: Up to approximately 25 weeks	

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase I

End point values	Phase 1 (24 mg capsule PO daily)	Phase 1 (48 mg capsule PO daily)	Phase 1 (120 mg capsule PO daily)	Phase 1 (170 mg capsule PO daily)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	5	5	3
Units: Participants				
Participants with at least 1 TEAE	3	5	5	3
Participants with ≥ Grade 3 TEAEs	2	4	3	3
Pts w/ any drug-related TEAE	3	3	5	3
Pts w/ drug-related TEAEs ≥ Gr3 (CTCAE)	1	1	1	0
Participants with any serious TEAEs	1	4	3	1
Participants with any drug-related serious TEAEs	0	0	1	0
Pts w/ TEAEs leading to drug discontinuation	0	2	2	1

End point values	Phase 1 (230 mg capsule PO daily)	Phase 1 (300 mg capsule PO daily)	Phase 1 (400 mg capsule PO daily)	Phase 1 (225 mg tablet PO daily)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	4	7	8
Units: Participants				
Participants with at least 1 TEAE	3	4	7	8
Participants with ≥ Grade 3 TEAEs	2	4	7	8
Pts w/ any drug-related TEAE	3	3	6	7
Pts w/ drug-related TEAEs ≥ Gr3 (CTCAE)	0	0	5	3
Participants with any serious TEAEs	2	4	6	6
Participants with any drug-related serious TEAEs	0	0	1	0
Pts w/ TEAEs leading to drug discontinuation	0	2	2	4

End point values	Phase 1 (275 mg tablet PO daily)			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Participants				
Participants with at least 1 TEAE	6			
Participants with ≥ Grade 3 TEAEs	6			
Pts w/ any drug-related TEAE	5			
Pts w/ drug-related TEAEs ≥ Gr3 (CTCAE)	4			
Participants with any serious TEAEs	6			
Participants with any drug-related serious TEAEs	3			
Pts w/ TEAEs leading to drug discontinuation	3			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (All Arms): Number of adverse events and serious adverse events as assessed by CTCAE criteria

End point title	Phase 2 (All Arms): Number of adverse events and serious adverse events as assessed by CTCAE criteria <sup>[10]</sup>
-----------------	---

End point description:

The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 387 weeks

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	52	59	28
Units: Participants				
Participants with at least 1 TEAE	48	51	59	28
Participants with ≥ Grade 3 TEAEs	38	40	49	21
Pts w/ ≥1 TEAE related to pelabresib	45	44	53	27
Pts w/ ≥Gr3 TEAEs related to pelabresib	27	21	33	14
Participants with any serious TEAEs	21	27	29	18
Pts w/ serious TEAEs related to pelabresib	4	4	2	6
Pts w/ TEAEs causing pelabresib interruption	20	16	32	13
Pts w/ TEAEs causing pelabresib dose reduction	16	10	15	7
Pts w/ TEAEs causing pelabresib discontinuation	12	12	17	7
Pts w/ TEAEs causing study discontinuation	11	11	18	9

End point values	Ph2 Arm3 MF JAKi-naïve –	Ph2 Arm4 ET – Monotherapy		
------------------	-----------------------------	------------------------------	--	--

	Combo Tx			
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	21		
Units: Participants				
Participants with at least 1 TEAE	84	21		
Participants with ≥ Grade 3 TEAEs	66	10		
Pts w/ ≥1 TEAE related to pelabresib	74	20		
Pts w/ ≥Gr3 TEAEs related to pelabresib	41	6		
Participants with any serious TEAEs	41	7		
Pts w/ serious TEAEs related to pelabresib	16	3		
Pts w/ TEAEs causing pelabresib interruption	39	9		
Pts w/ TEAEs causing pelabresib dose reduction	38	6		
Pts w/ TEAEs causing pelabresib discontinuation	22	3		
Pts w/ TEAEs causing study discontinuation	22	5		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (All Arms): Symptom improvement from the Patient Global Impression of Change (PGIC) at 12 and 24 weeks

End point title	Phase 2 (All Arms): Symptom improvement from the Patient Global Impression of Change (PGIC) at 12 and 24 weeks <sup>[11]</sup>
-----------------	--

End point description:

The Patient Global Impression of Change (PGIC) was a single-question, patient-reported assessment that asked individuals to rate their overall change in myeloproliferative neoplasm (MPN) symptoms since starting study treatment. The participants selected one of seven options, ranging from 'Very much improved' to 'Very much worse'. 'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39	43	47	25
Units: Participants				
PGIC status at Week 12 Improvement	28	36	22	18
PGIC status at Week 24 Improvement	20	29	27	16
PGIC status at Week 12 No change	7	2	15	4

PGIC status at Week 24 No change	10	3	12	6
PGIC status at Week 12 Worsening	4	5	10	3
PGIC status at Week 24 Worsening	2	5	4	0

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	80	19		
Units: Participants				
PGIC status at Week 12 Improvement	66	13		
PGIC status at Week 24 Improvement	58	8		
PGIC status at Week 12 No change	9	4		
PGIC status at Week 24 No change	15	3		
PGIC status at Week 12 Worsening	5	2		
PGIC status at Week 24 Worsening	6	4		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arms 1, 2 and 3): Percent Change from Baseline in Total Symptom Score (TSS) from the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) at 12 and 24 weeks

End point title	Phase 2 (Arms 1, 2 and 3): Percent Change from Baseline in Total Symptom Score (TSS) from the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) at 12 and 24 weeks <sup>[12]</sup>
-----------------	---

End point description:

The MFSAF (Myelofibrosis Symptom Assessment Form) was completed by participants every day for 7 days before Day 1 of each treatment cycle, including the 7 days before starting Cycle 1. It used a 24-hour recall format, asking participants to rate the worst severity of seven symptoms (fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain) during the past 24 hours. Each symptom was rated on a scale from 0 (Absent) to 10 (Worst Imaginable). The Total Symptom Score (TSS) was the sum of 7 symptoms (range: 0–70). 'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arms 1, 2 and 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	43	48	25
Units: Score on a scale				
arithmetic mean (standard deviation)				
Percent Change from baseline to Week 12	-38.77 (± 38.637)	-30.98 (± 35.394)	-27.18 (± 75.391)	-29.70 (± 36.106)
Percent Change from baseline to Week 24	-32.69 (± 36.474)	-39.82 (± 42.228)	-38.93 (± 61.818)	-44.73 (± 35.224)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	82			
Units: Score on a scale				
arithmetic mean (standard deviation)				
Percent Change from baseline to Week 12	-39.91 (± 69.251)			
Percent Change from baseline to Week 24	-47.43 (± 52.460)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arms 1, 2 and 3): Number of Participants who achieved a ≥ 50% reduction in Total Symptom Score (TSS) at 12 and 24 weeks

End point title	Phase 2 (Arms 1, 2 and 3): Number of Participants who achieved a ≥ 50% reduction in Total Symptom Score (TSS) at 12 and 24 weeks <sup>[13]</sup>
-----------------	--

End point description:

The proportion of study participants who experienced a reduction of at least 50% in their Total Symptom Score (TSS), as assessed using the Myelofibrosis Symptom Assessment Form (MFSAF v4.0), was evaluated at both 12 and 24 weeks relative to their baseline score.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arms 1, 2 and 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	52	59	28
Units: Percentage of Participants				
number (confidence interval 95%)				
MFSAF TSS50 response at week 12	33.3 (20.0 to 49.0)	31.3 (18.7 to 46.3)	36.2 (24.0 to 49.9)	33.3 (16.5 to 54.0)
MFSAF TSS50 response at week 24	15.6 (6.5 to 29.5)	34.7 (21.7 to 49.6)	36.2 (24.0 to 49.9)	40.7 (22.4 to 61.2)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: Percentage of Participants				
number (confidence interval 95%)				
MFSAF TSS50 response at week 12	52.4 (41.1 to 63.6)			
MFSAF TSS50 response at week 24	56.1 (44.7 to 67.0)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arms 1, 2 and 3): Number of Participants with Overall Splenic Response Rate (overall SVR35)

End point title	Phase 2 (Arms 1, 2 and 3): Number of Participants with Overall Splenic Response Rate (overall SVR35) <sup>[14]</sup>
-----------------	--

End point description:

Overall Splenic Response Rate (SVR35) was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), at any point between Cycle 1 Day 1 and the End of Study Visit, whichever occurred first.

End point type	Secondary
----------------	-----------

End point timeframe:

Through Phase II completion, an average of 6 years

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arms 1, 2 and 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	52	59	28
Units: Percentage of Participants				
number (confidence interval 95%)	16.7 (7.0 to 31.4)	28.8 (17.1 to 43.1)	30.8 (18.7 to 45.1)	25.0 (10.7 to 44.9)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: Percentage of Participants				
number (confidence interval 95%)	79.8 (69.6 to 87.7)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arms 1, 2 and 3): Duration of Overall Splenic Response (overall SVR35)

End point title	Phase 2 (Arms 1, 2 and 3): Duration of Overall Splenic Response (overall SVR35) <sup>[15]</sup>
-----------------	---

End point description:

Duration of Overall Splenic Response (overall SVR35) was defined as the time from the first occurrence of a at least 35% reduction in spleen volume from baseline until the earliest of the following: a reduction of less than 35% from baseline combined with an increase of more than 25% from the nadir in spleen volume (as measured by MRI or CT), or death. The nadir was defined as the lowest spleen volume recorded after baseline and up to the evaluation point at which the initial splenic response was achieved.

End point type	Secondary
----------------	-----------

End point timeframe:

From first onset of splenic response until loss of response, assessed up to approximately 6 years

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arms 1, 2 and 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	52	59	28
Units: Weeks				
median (confidence interval 95%)	24.1 (12.4 to 999)	73.1 (27.1 to 106.4)	180.9 (73.0 to 999)	228.4 (36.1 to 999)

<b>End point values</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: Weeks				
median (confidence interval 95%)	197.6 (95.7 to 999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Cohorts 1A and 2A): Number of Participants with Splenic Response Rate (SVR35) at 12 and 24 weeks

End point title	Phase 2 (Cohorts 1A and 2A): Number of Participants with Splenic Response Rate (SVR35) at 12 and 24 weeks <sup>[16]</sup>
-----------------	---

End point description:

Splenic Response Rate (SVR35) at 12 and 24 weeks was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as determined by imaging (MRI or CT), following 12 and 24 weeks of treatment, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1A and 2A)

<b>End point values</b>	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm2 MF JAKi combo – Cohort 2A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	59		
Units: Percentage of Participants				
number (confidence interval 95%)				
SVR35 at week 12	9.3 (2.6 to 22.1)	9.4 (3.1 to 20.7)		
SVR35 at week 24	0 (0 to 999)	16.4 (7.8 to 28.8)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Cohorts 1A and 2A): Duration of Red Blood Cell (RBC)

## Transfusion Independence (TI) in participants who enroll as Transfusion Dependent (TD)

End point title	Phase 2 (Cohorts 1A and 2A): Duration of Red Blood Cell (RBC) Transfusion Independence (TI) in participants who enroll as Transfusion Dependent (TD) <sup>[17]</sup>
-----------------	--

End point description:

Duration of Red Blood Cell (RBC) Transfusion Independence (TI) was defined as the longest continuous period during which participants, having achieved at least 12 weeks of transfusion independence, remained free from RBC transfusions.

End point type	Secondary
----------------	-----------

End point timeframe:

From first onset of TI to earliest onset of loss of TI, assessed up to approximately 6 years

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1A and 2A)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm2 MF JAKi combo – Cohort 2A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	59		
Units: Weeks				
median (full range (min-max))	35.8 (15.3 to 999)	68.0 (34.7 to 999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Cohorts 1A and 2A): Early anemic response rate in participants who enroll as Transfusion Dependent (TD)

End point title	Phase 2 (Cohorts 1A and 2A): Early anemic response rate in participants who enroll as Transfusion Dependent (TD) <sup>[18]</sup>
-----------------	--

End point description:

Early anemic response rate was defined as the proportion of participants who achieved an average increase of at least 1 g/dL in hemoglobin concentration over any rolling 8-week (56-day) period following baseline. This calculation was performed after applying the 14/3 day rule, which stipulates that hemoglobin measurements must be spaced at least 14 days apart, and that at least 3 such measurements are required within the 8-week window to ensure a reliable average. Importantly, this increase had to occur without any red blood cell (RBC) transfusions during the treatment period and up to the time of the latest hemoglobin assessment for each patient.

End point type	Secondary
----------------	-----------

End point timeframe:

Through Phase II completion, an average of 6 years

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1A and 2A)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm2 MF JAKi combo – Cohort 2A		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	59		
Units: Percentage of Participants				
number (confidence interval 95%)	18.6 (8.4 to 33.4)	21.7 (10.9 to 36.4)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants with Splenic Response Rate (SVR35) at 12 weeks

End point title	Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants with Splenic Response Rate (SVR35) at 12 weeks <sup>[19]</sup>
-----------------	--

End point description:

Splenic Response Rate (SVR35) at Week 12 was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), following 12 weeks of treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12 (Cycle 5 Day 1)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1B, 2B and Arm 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2B	Ph2 Arm3 MF JAKi-naïve – Combo Tx	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	28	84	
Units: Percentage of Participants				
number (confidence interval 95%)	15.4 (6.9 to 28.1)	10.7 (2.3 to 28.2)	66.7 (55.5 to 76.6)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Cohorts 1B, 2B, and Arm 3): Anemic response rate in participants who enroll as non-transfusion-dependent (non-TD)

End point title	Phase 2 (Cohorts 1B, 2B, and Arm 3): Anemic response rate in participants who enroll as non-transfusion-dependent (non-TD) <sup>[20]</sup>
-----------------	--

End point description:

Anemic response was defined as a sustained average increase in hemoglobin concentration of at least 1.5 g/dL over any rolling 12-week (84-day) period following baseline. This calculation excluded periods involving red blood cell (RBC) transfusions and was performed after applying the 14/3-day rule for valid

hemoglobin assessments. The response had to be maintained through to the most recent available hemoglobin measurement for each patient.

End point type	Secondary
----------------	-----------

End point timeframe:

Through Phase II completion, an average of 6 years

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Cohort 1B, 2B and Arm 3)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2B	Ph2 Arm3 MF JAKi-naïve – Combo Tx	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	52	28	84	
Units: Percentage of Participants				
number (confidence interval 95%)	47.1 (32.9 to 61.5)	21.4 (8.3 to 41.0)	35.4 (25.0 to 47.0)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 4): Percentage of participants who achieve a $\geq 50\%$ reduction from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total score

End point title	Phase 2 (Arm 4): Percentage of participants who achieve a $\geq 50\%$ reduction from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total score <sup>[21]</sup>
-----------------	--

End point description:

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a patient-reported questionnaire designed to measure symptom burden in participants with myeloproliferative neoplasms (MPNs). Participants rate the severity of several symptoms (such as fatigue, night sweats, itching, abdominal discomfort, bone pain, early satiety, and others) over the past 24 hours. Each symptom is scored on a scale from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be). The total score is the sum of all individual symptom scores, providing an overall measure of symptom burden. A 50% reduction in the MPN-SAF total score at 12 or 24 weeks means the patient's overall symptom burden has improved by half compared to their baseline (pre-treatment) score.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 12 weeks (Cycle 5, Day 1), 24 weeks (Cycle 9, Day 1)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 4)

<b>End point values</b>	Ph2 Arm4 ET – Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Percentage of Participants				
number (confidence interval 95%)				
MPN-SAF TSS50 response at week 12	25.0 (8.7 to 49.1)			
MPN-SAF TSS50 response at week 24	20.0 (5.7 to 43.7)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 4): Partial Hematological Response Rate (PHR)

End point title	Phase 2 (Arm 4): Partial Hematological Response Rate (PHR) <sup>[22]</sup>
-----------------	--

End point description:

Partial Hematological Response Rate (PHR) was defined as the proportion of participants who met the following criteria over two consecutive cycles up to the last administration of study treatment:

- Platelet count > 400-600 x 10<sup>9</sup>/L
- WBC count within normal range (i.e., ≤ 10 x 10<sup>9</sup>/L)
- Laboratory results confirmed after 1 cycle (after 3weeks)

End point type	Secondary
----------------	-----------

End point timeframe:

Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 4)

<b>End point values</b>	Ph2 Arm4 ET – Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Percentage of Participants				
number (confidence interval 95%)	38.1 (18.1 to 61.6)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 4): Overall Hematological Response Rate (OHR)

End point title	Phase 2 (Arm 4): Overall Hematological Response Rate
-----------------	--

End point description:

Confirmed Overall Hematological Response (OHR) Rate was defined as the proportion of participants with either a confirmed complete or a partial hematological response at any time.

End point type	Secondary
End point timeframe:	
Through Phase II completion, an average of 6 years	
Notes:	
[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: Endpoint only applicable to Phase II (Arm 4)	

<b>End point values</b>	Ph2 Arm4 ET – Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Percentage of Participants				
number (confidence interval 95%)	66.7 (43.0 to 85.4)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 4): Duration of Overall Hematological Response Rate (OHR)

End point title	Phase 2 (Arm 4): Duration of Overall Hematological Response Rate (OHR) <sup>[24]</sup>
End point description:	
Duration of Overall Hematological Response (OHR) Rate was defined as the time from when the overall hematological response was first met until the time at which the overall hematological response was lost, i.e., the criteria for an overall hematological response (CHR or PHR) were not observed or death occurred, whichever came first.	
End point type	Secondary
End point timeframe:	
Through Phase II completion, an average of 6 years	
Notes:	
[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: Endpoint only applicable to Phase II (Arm 4)	

<b>End point values</b>	Ph2 Arm4 ET – Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Weeks				
median (confidence interval 95%)	21.1 (9.1 to 33.1)			

## Statistical analyses

No statistical analyses for this end point

**Secondary: Phase 2 (Arm 4): Rate of hemorrhagic and thromboembolic (TE) events**

End point title	Phase 2 (Arm 4): Rate of hemorrhagic and thromboembolic (TE) events <sup>[25]</sup>
-----------------	---

End point description:

Rate of hemorrhagic and thromboembolic (TE) events was defined as the proportion of participants with hemorrhagic or thromboembolic events throughout the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Through Phase II completion, an average of 6 years

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 4)

<b>End point values</b>	Ph2 Arm4 ET – Monotherapy			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Percentage of Participants				
number (confidence interval 95%)	61.9 (38.4 to 81.9)			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Phase 2 (All Arms): Maximum observed plasma concentration (Cmax) of pelabresib**

End point title	Phase 2 (All Arms): Maximum observed plasma concentration (Cmax) of pelabresib <sup>[26]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

Cmax was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

<b>End point values</b>	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	39	38	16
Units: ng/mL				
geometric mean (geometric coefficient of variation)	1280 (± 29.1)	1350 (± 37.0)	1210 (± 40.0)	1190 (± 29.0)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	14		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	1070 (± 26.3)	2130 (± 24.7)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (All Arms): Time to reach maximum concentration (Tmax) of pelabresib

End point title	Phase 2 (All Arms): Time to reach maximum concentration (Tmax) of pelabresib <sup>[27]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

Tmax was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	39	38	16
Units: Hour				
median (full range (min-max))	1.94 (0.85 to 4.02)	1.58 (0.83 to 3.63)	1.90 (0.50 to 4.00)	1.81 (0.92 to 3.13)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	14		
Units: Hour				
median (full range (min-max))	1.71 (0.50 to 3.87)	2.08 (1.07 to 6.00)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (All Arms): Predose (trough) concentration at the end of a dosing interval (Ctrough) of pelabresib

End point title	Phase 2 (All Arms): Predose (trough) concentration at the end of a dosing interval (Ctrough) of pelabresib <sup>[28]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

Ctrough was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	37	36	16
Units: ng/mL				
geometric mean (geometric coefficient of variation)	120 (± 489.0)	201 (± 107.0)	244 (± 151.0)	162 (± 84.0)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	12		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	240 (± 79.1)	174 (± 112.0)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Phase 2 (All Arms): Area under the concentration–time curve from time zero to the last observed concentration (AUClast) of pelabresib**

End point title	Phase 2 (All Arms): Area under the concentration–time curve from time zero to the last observed concentration (AUClast) of pelabresib <sup>[29]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

AUClast was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	39	38	16
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	5660 (± 36.7)	5610 (± 35.5)	5190 (± 40.9)	4760 (± 26.7)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	14		
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	4380 (± 26.8)	9590 (± 28.7)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Phase 2 (All Arms): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of pelabresib**

End point title	Phase 2 (All Arms): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of pelabresib <sup>[30]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

AUC0-8,ss was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	31	34	14
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	6200 (± 35.3)	6470 (± 31.7)	5320 (± 38.1)	4930 (± 28.8)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	10		
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	4540 (± 25.3)	10800 (± 29.0)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (All Arms): Time of Last Measurable Concentration (Tlast) of pelabresib

End point title	Phase 2 (All Arms): Time of Last Measurable Concentration (Tlast) of pelabresib <sup>[31]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

Tlast was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (All Arms)

End point values	Ph2 Arm1 MF w/ prior JAKi – Cohort 1A	Ph2 Arm1 MF w/ prior JAKi – Cohort 1B	Ph2 Arm2 MF JAKi combo – Cohort 2A	Ph2 Arm2 MF JAKi combo – Cohort 2B
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	39	38	16
Units: Hour				
median (full range (min-max))	7.08 (4.50 to 9.00)	7.07 (2.58 to 8.08)	7.19 (6.10 to 8.05)	7.12 (7.00 to 8.17)

End point values	Ph2 Arm3 MF JAKi-naïve – Combo Tx	Ph2 Arm4 ET – Monotherapy		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	64	14		
Units: Hour				
median (full range (min-max))	7.08 (5.07 to 8.58)	7.08 (5.88 to 10.08)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 2 - Cohort 2A): Maximum observed plasma concentration (Cmax) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2A): Maximum observed plasma concentration (Cmax) of ruxolitinib <sup>[32]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

Cmax was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 2 - Cohort 2A)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2A			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2A, 5 mg	65.9 (± 56.5)			
Cohort 2A, 7.5 mg	142.0 (± 31.0)			
Cohort 2A, 10 mg	108.0 (± 29.3)			

Cohort 2A, 15 mg	310.0 (± 88.9)			
Cohort 2A, 20 mg	325.0 (± 37.7)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 2 - Cohort 2A): Time to reach maximum concentration (Tmax) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2A): Time to reach maximum concentration (Tmax) of ruxolitinib <sup>[33]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

Tmax was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 2 - Cohort 2A)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2A			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Hour				
median (full range (min-max))				
Cohort 2A, 5 mg	0.92 (0.50 to 2.00)			
Cohort 2A, 7.5 mg	1.00 (0.50 to 2.02)			
Cohort 2A, 10 mg	0.76 (0.50 to 1.50)			
Cohort 2A, 15 mg	1.55 (0.67 to 3.50)			
Cohort 2A, 20 mg	0.53 (0.33 to 1.58)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 2 - Cohort 2A): Predose (trough) concentration at the end of a dosing interval (Ctrough) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2A): Predose (trough) concentration
-----------------	---

## End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

C<sub>trough</sub> was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

## End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

## Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 2 - Cohort 2A)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2A			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2A, 5 mg	999 (± 999)			
Cohort 2A, 7.5 mg	14.7 (± 74.9)			
Cohort 2A, 10 mg	13.4 (± 81.6)			
Cohort 2A, 15 mg	74.6 (± 94.7)			
Cohort 2A, 20 mg	19.8 (± 54.2)			

## Statistical analyses

No statistical analyses for this end point

**Secondary: Phase 2 (Arm 2 - Cohort 2A): Area under the concentration–time curve from time zero to the last observed concentration (AUC<sub>last</sub>) of ruxolitinib**

End point title	Phase 2 (Arm 2 - Cohort 2A): Area under the concentration–time curve from time zero to the last observed concentration (AUC <sub>last</sub> ) of ruxolitinib <sup>[35]</sup>
-----------------	--

## End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

AUC<sub>last</sub> was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

## End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

## Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 2 - Cohort 2A)

<b>End point values</b>	Ph2 Arm2 MF JAKi combo – Cohort 2A			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2A, 5 mg	230 (± 63.3)			
Cohort 2A, 7.5 mg	390 (± 34.0)			
Cohort 2A, 10 mg	347 (± 44.7)			
Cohort 2A, 15 mg	1240 (± 64.7)			
Cohort 2A, 20 mg	829 (± 42.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 2 - Cohort 2A): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2A): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of ruxolitinib <sup>[36]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

AUC0-8,ss was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase 2 (Arm 2 - Cohort 2A)

<b>End point values</b>	Ph2 Arm2 MF JAKi combo – Cohort 2A			
Subject group type	Reporting group			
Number of subjects analysed	7			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2A, 5 mg	239 (± 64.5)			
Cohort 2A, 7.5 mg	369 (± 35.9)			
Cohort 2A, 10 mg	375 (± 47.2)			
Cohort 2A, 15 mg	999 (± 999)			
Cohort 2A, 20 mg	887 (± 42.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 2 - Cohort 2B): Maximum observed plasma concentration (C<sub>max</sub>) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2B): Maximum observed plasma concentration (C <sub>max</sub> ) of ruxolitinib <sup>[37]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

C<sub>max</sub> was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase 2 (Arm 2 - Cohort 2B)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2B			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2B, 5 mg	69.5 (± 27.8)			
Cohort 2B, 15 mg	999 (± 999)			
Cohort 2B, 20 mg	999 (± 999)			
Cohort 2B, 25 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 2 - Cohort 2B): Time to reach maximum concentration (T<sub>max</sub>) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2B): Time to reach maximum concentration (T <sub>max</sub> ) of ruxolitinib <sup>[38]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

T<sub>max</sub> was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase 2 (Arm 2 - Cohort 2B)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2B			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: Hour				
median (full range (min-max))				
Cohort 2B, 5 mg	1.57 (0.47 to 1.60)			
Cohort 2B, 15 mg	0.48 (0 to 999)			
Cohort 2B, 20 mg	0.53 (0 to 999)			
Cohort 2B, 25 mg	0.40 (0 to 999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 2 - Cohort 2B): Predose (trough) concentration at the end of a dosing interval (Ctrough) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2B): Predose (trough) concentration at the end of a dosing interval (Ctrough) of ruxolitinib <sup>[39]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

Ctrough was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase 2 (Arm 2 - Cohort 2B)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2B			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2B, 5 mg	8.49 (± 28.4)			
Cohort 2B, 15 mg	999 (± 999)			
Cohort 2B, 20 mg	999 (± 999)			
Cohort 2B, 25 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 2 - Cohort 2B): Area under the concentration–time curve from time zero to the last observed concentration (AUClast) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2B): Area under the concentration–time curve from time zero to the last observed concentration (AUClast) of ruxolitinib <sup>[40]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

AUClast was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase 2 (Arm 2 - Cohort 2B)

End point values	Ph2 Arm2 MF JAKi combo – Cohort 2B			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2B, 5 mg	207 (± 3.08)			
Cohort 2B, 15 mg	999 (± 999)			
Cohort 2B, 20 mg	999 (± 999)			
Cohort 2B, 25 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 2 - Cohort 2B): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of ruxolitinib

End point title	Phase 2 (Arm 2 - Cohort 2B): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of ruxolitinib <sup>[41]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual

sampling time points.

AUC<sub>0-8,ss</sub> was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase 2 (Arm 2 - Cohort 2B)

<b>End point values</b>	Ph2 Arm2 MF JAKi combo – Cohort 2B			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 2B, 5 mg	214 (± 3.67)			
Cohort 2B, 15 mg	999 (± 999)			
Cohort 2B, 20 mg	999 (± 999)			
Cohort 2B, 25 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 3): Maximum observed plasma concentration (C<sub>max</sub>) of ruxolitinib

End point title	Phase 2 (Arm 3): Maximum observed plasma concentration (C <sub>max</sub> ) of ruxolitinib <sup>[42]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

C<sub>max</sub> was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 3)

<b>End point values</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: ng/mL				
geometric mean (geometric coefficient				

of variation)				
Cohort 3, 5 mg	999 (± 999)			
Cohort 3, 10 mg	190 (± 28.6)			
Cohort 3, 15 mg	213 (± 34.7)			
Cohort 3, 20 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 3): Time to reach maximum concentration (Tmax) of ruxolitinib

End point title	Phase 2 (Arm 3): Time to reach maximum concentration (Tmax) of ruxolitinib <sup>[43]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

Tmax was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 3)

<b>End point values</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: Hour				
median (full range (min-max))				
Cohort 3, 5 mg	0.72 (0 to 999)			
Cohort 3, 10 mg	0.62 (0.28 to 7.00)			
Cohort 3, 15 mg	0.95 (0.22 to 3.87)			
Cohort 3, 20 mg	1.25 (0 to 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Phase 2 (Arm 3): Predose (trough) concentration at the end of a dosing interval (Ctrough) of ruxolitinib

End point title	Phase 2 (Arm 3): Predose (trough) concentration at the end of a dosing interval (Ctrough) of ruxolitinib <sup>[44]</sup>
-----------------	--

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

Ctrough was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 3)

<b>End point values</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 3, 5 mg	999 (± 999)			
Cohort 3, 10 mg	25.3 (± 99.2)			
Cohort 3, 15 mg	31.4 (± 58.1)			
Cohort 3, 20 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 3): Area under the concentration–time curve from time zero to the last observed concentration (AUClast) of ruxolitinib

End point title	Phase 2 (Arm 3): Area under the concentration–time curve from time zero to the last observed concentration (AUClast) of ruxolitinib <sup>[45]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

AUClast was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 3)

<b>End point values</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 3, 5 mg	999 (± 999)			
Cohort 3, 10 mg	519 (± 54.8)			
Cohort 3, 15 mg	677 (± 33.9)			
Cohort 3, 20 mg	999 (± 999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2 (Arm 3): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of ruxolitinib

End point title	Phase 2 (Arm 3): Area under the concentration–time curve from time zero to 8 hours post-dose at steady state (AUC0-8,ss) of ruxolitinib <sup>[46]</sup>
-----------------	---

End point description:

Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

AUC0-8,ss was listed and summarized using descriptive statistics.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Endpoint only applicable to Phase II (Arm 3)

<b>End point values</b>	Ph2 Arm3 MF JAKi-naïve – Combo Tx			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)				
Cohort 3, 5 mg	999 (± 999)			
Cohort 3, 10 mg	587 (± 45.5)			
Cohort 3, 15 mg	696 (± 34.7)			
Cohort 3, 20 mg	999 (± 999)			

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AEs) were collected from first dose of study medication up to 30 days after last dose of pelabresib (CPI-0610) (end of study), assessed up to approximately 10 years.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Phase 1 120 mg capsule PO daily
-----------------------	---------------------------------

Reporting group description:

Phase 1 120 mg capsule PO daily

Reporting group title	Phase 1 24 mg capsule PO daily
-----------------------	--------------------------------

Reporting group description:

Phase 1 24 mg capsule PO daily

Reporting group title	Phase 1 48 mg capsule PO daily
-----------------------	--------------------------------

Reporting group description:

Phase 1 48 mg capsule PO daily

Reporting group title	Phase 1 400 mg capsule PO daily
-----------------------	---------------------------------

Reporting group description:

Phase 1 400 mg capsule PO daily

Reporting group title	Phase 1 225 mg tablet PO daily
-----------------------	--------------------------------

Reporting group description:

Phase 1 225 mg tablet PO daily

Reporting group title	Phase 1 300 mg capsule PO daily
-----------------------	---------------------------------

Reporting group description:

Phase 1 300 mg capsule PO daily

Reporting group title	Phase 1 230 mg capsule PO daily
-----------------------	---------------------------------

Reporting group description:

Phase 1 230 mg capsule PO daily

Reporting group title	Phase 1 170 mg capsule PO daily
-----------------------	---------------------------------

Reporting group description:

Phase 1 170 mg capsule PO daily

Reporting group title	Phase 1 275 mg tablet PO daily
-----------------------	--------------------------------

Reporting group description:

Phase 1 275 mg tablet PO daily

Reporting group title	Phase 1 overall
-----------------------	-----------------

Reporting group description:

Phase 1 overall

Reporting group title	Phase 2 Arm 1 1A
-----------------------	------------------

Reporting group description:

Phase 2 Arm 1 1A

Reporting group title	Phase 2 Arm 1 1B
-----------------------	------------------

Reporting group description:

Phase 2 Arm 1 1B

Reporting group title	Phase 2 Arm 2 2A
Reporting group description: Phase 2 Arm 2 2A	
Reporting group title	Phase 2 Arm 2 2B
Reporting group description: Phase 2 Arm 2 2B	
Reporting group title	Phase 2 Arm 3
Reporting group description: Phase 2 Arm 3	
Reporting group title	Phase 2 Arm 4
Reporting group description: Phase 2 Arm 4	
Reporting group title	Phase 2 Overall
Reporting group description: Phase 2 Overall	

<b>Serious adverse events</b>	Phase 1 120 mg capsule PO daily	Phase 1 24 mg capsule PO daily	Phase 1 48 mg capsule PO daily
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 5 (60.00%)	1 / 3 (33.33%)	4 / 5 (80.00%)
number of deaths (all causes)	2	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Bowen's disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Breast cancer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematopoietic neoplasm			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratoacanthoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine carcinoma of the skin			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian neoplasm			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of head and neck			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Peripheral ischaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Serum sickness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bronchospasm			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Investigations</b>			
Blast cell count increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Extradural haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hip fracture			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac iron overload			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic coronary syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dilated cardiomyopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior sagittal sinus thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 3 (33.33%)	2 / 5 (40.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Leukocytosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Cutaneous vasculitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst ruptured			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermo-hypodermatitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphyema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex reactivation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia acinetobacter			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 1 400 mg capsule PO daily	Phase 1 225 mg tablet PO daily	Phase 1 300 mg capsule PO daily
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 7 (85.71%)	6 / 8 (75.00%)	4 / 4 (100.00%)
number of deaths (all causes)	1	1	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Glioblastoma	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematopoietic neoplasm	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratoacanthoma	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine carcinoma of the skin	subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal squamous cell carcinoma				

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian neoplasm			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of head and neck			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Serum sickness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Dyspnoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	2 / 7 (28.57%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Blast cell count increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Extradural haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pelvic fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac iron overload			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic coronary syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dilated cardiomyopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior sagittal sinus thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	2 / 7 (28.57%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			

Cutaneous vasculitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst ruptured			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bacteraemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermo-hypodermatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			

subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Endocarditis bacterial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex reactivation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia acinetobacter			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Phase 1 230 mg capsule PO daily	Phase 1 170 mg capsule PO daily	Phase 1 275 mg tablet PO daily
-------------------------------	---------------------------------	---------------------------------	--------------------------------

Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	1 / 3 (33.33%)	6 / 6 (100.00%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematopoietic neoplasm			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratoacanthoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine carcinoma of the skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian neoplasm			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of head and neck			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Serum sickness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Organising pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blast cell count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Extradural haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac iron overload			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic coronary syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dilated cardiomyopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior sagittal sinus thrombosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Cutaneous vasculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst ruptured			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermo-hypodermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Escherichia infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex reactivation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia acinetobacter			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 1 overall	Phase 2 Arm 1 1A	Phase 2 Arm 1 1B
Total subjects affected by serious adverse events			
subjects affected / exposed	33 / 44 (75.00%)	18 / 48 (37.50%)	23 / 52 (44.23%)
number of deaths (all causes)	8	6	3
number of deaths resulting from adverse events	0	0	0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	5 / 44 (11.36%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 4	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematopoietic neoplasm			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Invasive breast carcinoma				
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Keratoacanthoma				
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Malignant melanoma				
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Metastatic squamous cell carcinoma				
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin				
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0	
Oropharyngeal squamous cell carcinoma				
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Ovarian neoplasm				
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Squamous cell carcinoma of head and neck				
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	

Squamous cell carcinoma of skin subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	4 / 44 (9.09%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	3 / 44 (6.82%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 3	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Serum sickness			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bronchospasm			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Organising pneumonia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			

subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blast cell count increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			

subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Extradural haematoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cardiac failure			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac iron overload			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic coronary syndrome			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dilated cardiomyopathy			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior sagittal sinus thrombosis			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	9 / 44 (20.45%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	3 / 44 (6.82%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	2 / 3	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haematoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	3 / 44 (6.82%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Cutaneous vasculitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst ruptured			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal haematoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
COVID-19 pneumonia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermo-hypodermatitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex reactivation			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	4 / 44 (9.09%)	4 / 48 (8.33%)	3 / 52 (5.77%)
occurrences causally related to treatment / all	0 / 5	1 / 4	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonia acinetobacter			

subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	3 / 44 (6.82%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	1 / 52 (1.92%)
occurrences causally related to treatment / all	0 / 1	2 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 2 Arm 2 2A	Phase 2 Arm 2 2B	Phase 2 Arm 3
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 59 (49.15%)	18 / 28 (64.29%)	40 / 84 (47.62%)
number of deaths (all causes)	3	3	7
number of deaths resulting from adverse events	0	1	2

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myeloid leukaemia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bowen's disease			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematopoietic neoplasm			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Invasive breast carcinoma				
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Keratoacanthoma				
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Malignant melanoma				
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Metastatic squamous cell carcinoma				
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin				
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Oropharyngeal squamous cell carcinoma				
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Ovarian neoplasm				
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Squamous cell carcinoma of head and neck				
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	

Squamous cell carcinoma of skin subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	4 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	6 / 84 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Fatigue			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 2
Non-cardiac chest pain			

subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences causally related to treatment / all	0 / 1	0 / 2	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Serum sickness			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Organising pneumonia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			

subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blast cell count increased			
subjects affected / exposed	1 / 59 (1.69%)	3 / 28 (10.71%)	5 / 84 (5.95%)
occurrences causally related to treatment / all	0 / 1	0 / 3	2 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Extradural haematoma			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac iron overload			

subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic coronary syndrome			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dilated cardiomyopathy			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain stem haemorrhage			

subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior sagittal sinus thrombosis			

subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 59 (3.39%)	5 / 28 (17.86%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 2	2 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukostasis syndrome			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic infarction			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenomegaly			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			

subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haematoma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Cutaneous vasculitis			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Renal cyst ruptured			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal haematoma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			

subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspergillus infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
COVID-19 pneumonia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	4 / 84 (4.76%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Clostridium difficile infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermo-hypodermatitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal bacteraemia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			

subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex reactivation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocardiosis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	4 / 59 (6.78%)	2 / 28 (7.14%)	5 / 84 (5.95%)
occurrences causally related to treatment / all	0 / 4	1 / 2	2 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia acinetobacter			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia pneumococcal			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia staphylococcal			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Post procedural infection			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 2
Septic shock			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	2 / 84 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Urosepsis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 2 Arm 4	Phase 2 Overall	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 21 (23.81%)	133 / 292 (45.55%)	
number of deaths (all causes)	0	22	
number of deaths resulting from adverse events	0	3	

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bowen's disease			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer metastatic			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	1 / 21 (4.76%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematopoietic neoplasm			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Invasive breast carcinoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoacanthoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian neoplasm			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of head and neck			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Squamous cell carcinoma of skin subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	4 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transformation to acute myeloid leukaemia			
subjects affected / exposed	0 / 21 (0.00%)	9 / 292 (3.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chills			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Drug withdrawal syndrome			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Fatigue			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	1 / 2	
Non-cardiac chest pain			

subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences causally related to treatment / all	0 / 0	2 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Serum sickness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bronchospasm			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 21 (4.76%)	5 / 292 (1.71%)	
occurrences causally related to treatment / all	1 / 1	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	

Organising pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 21 (4.76%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			

subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 3	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blast cell count increased			
subjects affected / exposed	0 / 21 (0.00%)	9 / 292 (3.08%)	
occurrences causally related to treatment / all	0 / 0	2 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Extradural haematoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute left ventricular failure			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiac failure			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac iron overload			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic coronary syndrome			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dilated cardiomyopathy			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Brain stem haemorrhage			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral infarction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebrovascular accident			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metabolic encephalopathy			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior sagittal sinus thrombosis			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 21 (0.00%)	11 / 292 (3.77%)	
occurrences causally related to treatment / all	0 / 0	2 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukostasis syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenomegaly			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 21 (4.76%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haematoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertransaminasaemia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Cutaneous vasculitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Haematuria			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	1 / 21 (4.76%)	6 / 292 (2.05%)	
occurrences causally related to treatment / all	1 / 1	2 / 6	
deaths causally related to treatment / all	0 / 0	1 / 1	
Renal cyst ruptured			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal haematoma			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint effusion			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspergillus infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences causally related to treatment / all	0 / 0	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 2	
COVID-19 pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences causally related to treatment / all	0 / 0	2 / 5	
deaths causally related to treatment / all	0 / 0	1 / 1	
Clostridium difficile infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermo-hypodermatitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empyema			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis bacterial			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fournier's gangrene			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes simplex reactivation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nocardiosis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	18 / 292 (6.16%)	
occurrences causally related to treatment / all	0 / 0	4 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia acinetobacter			

subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia pneumococcal			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Post procedural infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			

subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	1 / 2	
Septic shock			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Streptococcal sepsis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Urosepsis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	1 / 21 (4.76%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 21 (4.76%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences causally related to treatment / all	0 / 0	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Phase 1 120 mg capsule PO daily	Phase 1 24 mg capsule PO daily	Phase 1 48 mg capsule PO daily
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	3 / 3 (100.00%)	5 / 5 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Hot flush			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Hypotension			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	2 / 5 (40.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Chills			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0

Early satiety			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	4 / 5 (80.00%)	2 / 3 (66.67%)	3 / 5 (60.00%)
occurrences (all)	4	2	4
Gait disturbance			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Nodule			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	3 / 5 (60.00%)
occurrences (all)	0	0	3
Pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Peripheral swelling			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Reproductive system and breast disorders			
Genital lesion			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 5 (20.00%)	2 / 3 (66.67%)	0 / 5 (0.00%)
occurrences (all)	1	2	0
Dyspnoea			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	1 / 5 (20.00%)
occurrences (all)	0	1	1
Dyspnoea exertional			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Hypoxia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinus pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Upper-airway cough syndrome			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Anxiety			
subjects affected / exposed	0 / 5 (0.00%)	2 / 3 (66.67%)	1 / 5 (20.00%)
occurrences (all)	0	2	1
Delirium			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Activated partial thromboplastin time prolonged			

subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Blast cell count increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Blood phosphorus increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Cardiac murmur			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Electrocardiogram QRS complex abnormal			

subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Haematocrit increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 5 (0.00%)	2 / 3 (66.67%)	0 / 5 (0.00%)
occurrences (all)	0	3	0
Transaminases increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Troponin T increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Weight increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nail injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Procedural site reaction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Vascular access site complication			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Angina pectoris			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Atrioventricular block			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyperdynamic left ventricle			

subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Palpitations			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Cerebrovascular accident			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	1 / 5 (20.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	1	1	0
Dysgeusia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Dysarthria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	2 / 5 (40.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences (all)	2	0	2
Lethargy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Memory impairment subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	1 / 5 (20.00%) 1
Paraesthesia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Taste disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Blood and lymphatic system disorders			
Leukocytosis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 3 (33.33%) 1	1 / 5 (20.00%) 1
Anaemia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 2	1 / 3 (33.33%) 1	1 / 5 (20.00%) 1
Lymphadenopathy			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Spleen disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Thrombocytosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Ear haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Ear pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Eye haemorrhage			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Vision blurred			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	1 / 5 (20.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	2	1	0
Dry mouth			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Enterocolitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1

Eructation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	3
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Melaena			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Mouth haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	4 / 5 (80.00%)	2 / 3 (66.67%)	3 / 5 (60.00%)
occurrences (all)	5	2	4
Stomatitis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1

Oral disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	1 / 5 (20.00%) 1
Proctalgia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	2 / 5 (40.00%) 2
Hepatobiliary disorders Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis acneiform subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Hyperhidrosis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Petechiae subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Rash			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Rash macular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Skin lesion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin induration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Skin ulcer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Nocturia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Bone cyst			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Bursitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gouty arthritis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Groin pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	3
Joint swelling			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Rhabdomyolysis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Cellulitis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Herpes simplex reactivation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Localised infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Oral herpes			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 3 (33.33%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
Orchitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Septic shock			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Tooth infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3	0 / 3 (0.00%) 0	1 / 5 (20.00%) 2
Dehydration subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Folate deficiency subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Gout subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0	0 / 5 (0.00%) 0
Hypermagnesaemia			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Iron overload			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tumour lysis syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			

subjects affected / exposed	0 / 5 (0.00%)	0 / 3 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 1 400 mg capsule PO daily	Phase 1 225 mg tablet PO daily	Phase 1 300 mg capsule PO daily
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 7 (100.00%)	8 / 8 (100.00%)	4 / 4 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Asthenia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0

Chills			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Early satiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	5 / 7 (71.43%)	3 / 8 (37.50%)	0 / 4 (0.00%)
occurrences (all)	6	3	0
Gait disturbance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			
subjects affected / exposed	1 / 7 (14.29%)	2 / 8 (25.00%)	1 / 4 (25.00%)
occurrences (all)	1	2	1
Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1

Peripheral swelling subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Reproductive system and breast disorders			
Genital lesion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	0 / 4 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	3 / 8 (37.50%) 6	1 / 4 (25.00%) 1
Hypoxia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	0 / 4 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	1 / 4 (25.00%) 1
Pleural effusion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 8 (0.00%) 0	0 / 4 (0.00%) 0
Productive cough			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sinus pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	2 / 7 (28.57%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Blast cell count increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Blood bilirubin increased			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Blood creatinine increased			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Blood phosphorus increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Blood uric acid increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cardiac murmur			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QRS complex abnormal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Haematocrit increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
Neutrophil count decreased			
subjects affected / exposed	2 / 7 (28.57%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	5	2	0
Platelet count decreased			
subjects affected / exposed	2 / 7 (28.57%)	2 / 8 (25.00%)	0 / 4 (0.00%)
occurrences (all)	2	2	0
Transaminases increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Weight increased			

subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	2 / 7 (28.57%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	7	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Nail injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Procedural site reaction			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Skin laceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vascular access site complication			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Angina pectoris			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Atrioventricular block			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hyperdynamic left ventricle			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cerebrovascular accident			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	1 / 7 (14.29%)	3 / 8 (37.50%)	1 / 4 (25.00%)
occurrences (all)	1	3	1
Dysarthria			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Headache			
subjects affected / exposed	2 / 7 (28.57%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Lethargy			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Memory impairment			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukocytosis			

subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Anaemia			
subjects affected / exposed	4 / 7 (57.14%)	1 / 8 (12.50%)	1 / 4 (25.00%)
occurrences (all)	7	1	1
Lymphadenopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
Spleen disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
Thrombocytosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ear haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hypoacusis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Tinnitus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Eye disorders			
Eye haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Anal incontinence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Diarrhoea			
subjects affected / exposed	3 / 7 (42.86%)	5 / 8 (62.50%)	4 / 4 (100.00%)
occurrences (all)	3	8	4
Dry mouth			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Dysphagia			

subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Enterocolitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Melaena			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Mouth haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nausea			

subjects affected / exposed	2 / 7 (28.57%)	5 / 8 (62.50%)	2 / 4 (50.00%)
occurrences (all)	2	5	2
Stomatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oral disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Proctalgia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	3 / 7 (42.86%)	1 / 8 (12.50%)	1 / 4 (25.00%)
occurrences (all)	3	2	1
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis acneiform			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Petechiae			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rash macular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin induration			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Dysuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Haematuria			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Micturition urgency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
Bone cyst			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	1	2	0
Gouty arthritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Groin pain			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Musculoskeletal disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
Pain in jaw			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rhabdomyolysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			

Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Folliculitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Herpes simplex reactivation			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Localised infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Orchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Otitis media			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Septic shock			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0

Staphylococcal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 7 (28.57%)	5 / 8 (62.50%)	1 / 4 (25.00%)
occurrences (all)	2	5	1
Dehydration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Folate deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			

subjects affected / exposed	0 / 7 (0.00%)	2 / 8 (25.00%)	1 / 4 (25.00%)
occurrences (all)	0	2	1
Hyperkalaemia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Hypermagnesaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Hypertriglyceridaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	2 / 7 (28.57%)	2 / 8 (25.00%)	0 / 4 (0.00%)
occurrences (all)	3	2	0
Hypokalaemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	1 / 4 (25.00%)
occurrences (all)	0	1	1
Hypocalcaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 7 (0.00%)	2 / 8 (25.00%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
Hypophosphataemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Iron overload			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tumour lysis syndrome			

subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 8 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 1 230 mg capsule PO daily	Phase 1 170 mg capsule PO daily	Phase 1 275 mg tablet PO daily
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	5 / 6 (83.33%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Hypertension			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
General disorders and administration site conditions			

Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	1 / 6 (16.67%)
occurrences (all)	0	2	2
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Nodule			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2

Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Genital lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Dyspnoea			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Sinus pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Depression subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blast cell count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Bilirubin conjugated increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Blood phosphorus increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood uric acid increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac murmur			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QRS complex abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematocrit increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Transaminases increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Weight decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	5
Weight increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nail injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Procedural site reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vascular access site complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Atrioventricular block			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperdynamic left ventricle			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Dysarthria			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Taste disorder			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Blood and lymphatic system disorders			
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
Lymphadenopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Spleen disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Thrombocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Eye disorders Eye haemorrhage subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0	2 / 6 (33.33%) 2
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Anal incontinence subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Diarrhoea subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	2 / 6 (33.33%) 5
Dry mouth			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Enterocolitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Melaena			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mouth haemorrhage			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Mouth ulceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	3 / 3 (100.00%)	2 / 6 (33.33%)
occurrences (all)	0	4	4
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Oral disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Proctalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	3 / 6 (50.00%)
occurrences (all)	0	3	5
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis acneiform			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Rash			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Rash macular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Skin discolouration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Skin lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin induration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Renal and urinary disorders			

Acute kidney injury subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Dysuria subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Micturition urgency subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 6 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 2	0 / 6 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 6 (16.67%) 1
Bone cyst subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Bursitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 6 (0.00%) 0
Bone pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gouty arthritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal disorder			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Pain in jaw			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhabdomyolysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Herpes simplex reactivation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Influenza			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Localised infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Orchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Septic shock			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	2 / 6 (33.33%)
occurrences (all)	2	2	3
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Folate deficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gout			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	2
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Iron overload			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tumour lysis syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Phase 1 overall	Phase 2 Arm 1 1A	Phase 2 Arm 1 1B
Total subjects affected by non-serious adverse events			
subjects affected / exposed	43 / 44 (97.73%)	48 / 48 (100.00%)	50 / 52 (96.15%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	3
Squamous cell carcinoma			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Haematoma			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	2	0	3
Hypertension			
subjects affected / exposed	4 / 44 (9.09%)	1 / 48 (2.08%)	4 / 52 (7.69%)
occurrences (all)	4	1	5
Hot flush			

subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	2	0	1
Hypotension			
subjects affected / exposed	4 / 44 (9.09%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	4	0	3
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Asthenia			
subjects affected / exposed	4 / 44 (9.09%)	9 / 48 (18.75%)	3 / 52 (5.77%)
occurrences (all)	4	9	3
Chills			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	2	1	2
Early satiety			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	4 / 52 (7.69%)
occurrences (all)	0	3	5
Fatigue			
subjects affected / exposed	20 / 44 (45.45%)	14 / 48 (29.17%)	17 / 52 (32.69%)
occurrences (all)	23	18	19
Gait disturbance			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	1	1	2
Influenza like illness			
subjects affected / exposed	0 / 44 (0.00%)	3 / 48 (6.25%)	2 / 52 (3.85%)
occurrences (all)	0	5	2
Mucosal inflammation			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Nodule			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Non-cardiac chest pain			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	1 / 52 (1.92%)
occurrences (all)	1	3	1
Oedema peripheral			
subjects affected / exposed	9 / 44 (20.45%)	13 / 48 (27.08%)	8 / 52 (15.38%)
occurrences (all)	9	13	11
Pain			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Pyrexia			
subjects affected / exposed	5 / 44 (11.36%)	8 / 48 (16.67%)	6 / 52 (11.54%)
occurrences (all)	5	10	8
Peripheral swelling			
subjects affected / exposed	0 / 44 (0.00%)	3 / 48 (6.25%)	0 / 52 (0.00%)
occurrences (all)	0	4	0
Reproductive system and breast disorders			
Genital lesion			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	6 / 44 (13.64%)	9 / 48 (18.75%)	11 / 52 (21.15%)
occurrences (all)	6	10	17
Dyspnoea			
subjects affected / exposed	4 / 44 (9.09%)	11 / 48 (22.92%)	10 / 52 (19.23%)
occurrences (all)	4	14	12
Dyspnoea exertional			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Epistaxis			

subjects affected / exposed	6 / 44 (13.64%)	6 / 48 (12.50%)	7 / 52 (13.46%)
occurrences (all)	10	7	17
Hypoxia			
subjects affected / exposed	2 / 44 (4.55%)	2 / 48 (4.17%)	0 / 52 (0.00%)
occurrences (all)	2	2	0
Nasal congestion			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	2	1	1
Oropharyngeal pain			
subjects affected / exposed	3 / 44 (6.82%)	2 / 48 (4.17%)	2 / 52 (3.85%)
occurrences (all)	3	2	2
Pleural effusion			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	1	1	2
Productive cough			
subjects affected / exposed	0 / 44 (0.00%)	3 / 48 (6.25%)	2 / 52 (3.85%)
occurrences (all)	0	3	2
Rhinorrhoea			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	2 / 52 (3.85%)
occurrences (all)	0	2	2
Pulmonary oedema			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	1	1	1
Sinus pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	3 / 52 (5.77%)
occurrences (all)	1	1	3
Wheezing			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	1 / 52 (1.92%)
occurrences (all)	1	2	1

Anxiety			
subjects affected / exposed	3 / 44 (6.82%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	3	0	1
Delirium			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Insomnia			
subjects affected / exposed	2 / 44 (4.55%)	2 / 48 (4.17%)	4 / 52 (7.69%)
occurrences (all)	2	2	4
Depression			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	0 / 52 (0.00%)
occurrences (all)	1	2	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	5 / 44 (11.36%)	1 / 48 (2.08%)	4 / 52 (7.69%)
occurrences (all)	5	1	4
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	1	0	2
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 44 (6.82%)	3 / 48 (6.25%)	4 / 52 (7.69%)
occurrences (all)	4	3	4
Blast cell count increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 44 (4.55%)	3 / 48 (6.25%)	2 / 52 (3.85%)
occurrences (all)	3	4	2
Blood bilirubin increased			
subjects affected / exposed	2 / 44 (4.55%)	3 / 48 (6.25%)	1 / 52 (1.92%)
occurrences (all)	2	3	1
Blood creatinine increased			

subjects affected / exposed	4 / 44 (9.09%)	3 / 48 (6.25%)	4 / 52 (7.69%)
occurrences (all)	5	3	5
Blood phosphorus increased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Blood uric acid increased			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Cardiac murmur			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Ejection fraction decreased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Electrocardiogram QRS complex abnormal			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	2	0	1
Haematocrit increased			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	1	1	2
Lymphocyte count decreased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	4	0	2
Neutrophil count decreased			
subjects affected / exposed	4 / 44 (9.09%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	8	0	0
Platelet count decreased			

subjects affected / exposed	8 / 44 (18.18%)	5 / 48 (10.42%)	8 / 52 (15.38%)
occurrences (all)	9	8	12
Transaminases increased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Troponin T increased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	5 / 44 (11.36%)	9 / 48 (18.75%)	14 / 52 (26.92%)
occurrences (all)	7	9	16
Weight increased			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	4 / 52 (7.69%)
occurrences (all)	1	0	5
White blood cell count decreased			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	7	2	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 44 (2.27%)	4 / 48 (8.33%)	9 / 52 (17.31%)
occurrences (all)	1	4	11
Fall			
subjects affected / exposed	1 / 44 (2.27%)	3 / 48 (6.25%)	10 / 52 (19.23%)
occurrences (all)	1	3	12
Nail injury			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Procedural site reaction			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Skin laceration			

subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	1 / 52 (1.92%)
occurrences (all)	1	2	1
Vascular access site complication			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Wound			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	3 / 44 (6.82%)	3 / 48 (6.25%)	1 / 52 (1.92%)
occurrences (all)	3	4	1
Angina pectoris			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Atrioventricular block			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Hyperdynamic left ventricle			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Palpitations			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	3 / 52 (5.77%)
occurrences (all)	1	2	3
Sinus tachycardia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	1	0	3
Tachycardia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	1	0	3
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Cerebrovascular accident			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Dizziness			
subjects affected / exposed	3 / 44 (6.82%)	7 / 48 (14.58%)	10 / 52 (19.23%)
occurrences (all)	3	8	14
Dysgeusia			
subjects affected / exposed	9 / 44 (20.45%)	10 / 48 (20.83%)	16 / 52 (30.77%)
occurrences (all)	9	12	18
Dysarthria			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	8 / 44 (18.18%)	6 / 48 (12.50%)	14 / 52 (26.92%)
occurrences (all)	8	7	25
Lethargy			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Memory impairment			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Migraine			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Neuropathy peripheral			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	1	0	3
Paraesthesia			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	1 / 52 (1.92%)
occurrences (all)	0	2	1
Presyncope			

subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 48 (0.00%) 0	0 / 52 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 48 (0.00%) 0	0 / 52 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 48 (0.00%) 0	0 / 52 (0.00%) 0
Taste disorder subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	1 / 48 (2.08%) 2	2 / 52 (3.85%) 2
Blood and lymphatic system disorders			
Leukocytosis subjects affected / exposed occurrences (all)	3 / 44 (6.82%) 3	1 / 48 (2.08%) 1	2 / 52 (3.85%) 2
Anaemia subjects affected / exposed occurrences (all)	12 / 44 (27.27%) 16	17 / 48 (35.42%) 28	15 / 52 (28.85%) 19
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 44 (2.27%) 1	0 / 48 (0.00%) 0	0 / 52 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	4 / 44 (9.09%) 4	1 / 48 (2.08%) 1	1 / 52 (1.92%) 1
Spleen disorder subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	3 / 48 (6.25%) 3	1 / 52 (1.92%) 1
Thrombocytopenia subjects affected / exposed occurrences (all)	4 / 44 (9.09%) 4	18 / 48 (37.50%) 34	12 / 52 (23.08%) 16
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 44 (0.00%) 0	0 / 48 (0.00%) 0	4 / 52 (7.69%) 4
Ear and labyrinth disorders Ear discomfort			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Ear haemorrhage			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	1	1	1
Hypoacusis			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	1	1	1
Tinnitus			
subjects affected / exposed	0 / 44 (0.00%)	3 / 48 (6.25%)	0 / 52 (0.00%)
occurrences (all)	0	3	0
Eye disorders			
Eye haemorrhage			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Vision blurred			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	1	0	2
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	6 / 52 (11.54%)
occurrences (all)	1	3	6
Abdominal distension			
subjects affected / exposed	2 / 44 (4.55%)	6 / 48 (12.50%)	10 / 52 (19.23%)
occurrences (all)	2	6	15
Abdominal pain			
subjects affected / exposed	6 / 44 (13.64%)	11 / 48 (22.92%)	11 / 52 (21.15%)
occurrences (all)	6	14	12
Abdominal pain upper			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	6 / 52 (11.54%)
occurrences (all)	1	2	7
Anal incontinence			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	4 / 44 (9.09%)	11 / 48 (22.92%)	14 / 52 (26.92%)
occurrences (all)	4	11	18
Diarrhoea			
subjects affected / exposed	17 / 44 (38.64%)	15 / 48 (31.25%)	26 / 52 (50.00%)
occurrences (all)	24	28	44
Dry mouth			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Dyspepsia			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	2	1	1
Dysphagia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Enterocolitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Eructation			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	2 / 44 (4.55%)	3 / 48 (6.25%)	1 / 52 (1.92%)
occurrences (all)	2	3	1
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 44 (2.27%)	3 / 48 (6.25%)	1 / 52 (1.92%)
occurrences (all)	1	3	1
Gingival bleeding			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	2	0
Gingival pain			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	3	0	0
Haemorrhoidal haemorrhage			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Melaena			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Mouth haemorrhage			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Mouth ulceration			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	0	1	2
Nausea			
subjects affected / exposed	23 / 44 (52.27%)	18 / 48 (37.50%)	23 / 52 (44.23%)
occurrences (all)	28	24	34
Stomatitis			
subjects affected / exposed	3 / 44 (6.82%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	3	1	2
Oral disorder			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Proctalgia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	13 / 44 (29.55%)	7 / 48 (14.58%)	10 / 52 (19.23%)
occurrences (all)	17	9	16
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 44 (0.00%)	4 / 48 (8.33%)	1 / 52 (1.92%)
occurrences (all)	0	10	1
Skin and subcutaneous tissue disorders			
Dermatitis acneiform			

subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	0	1	4
Dry skin			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	1	0	2
Erythema			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	4 / 52 (7.69%)
occurrences (all)	0	0	4
Hyperhidrosis			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	3 / 52 (5.77%)
occurrences (all)	0	2	4
Night sweats			
subjects affected / exposed	1 / 44 (2.27%)	5 / 48 (10.42%)	7 / 52 (13.46%)
occurrences (all)	1	7	8
Petechiae			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	3 / 52 (5.77%)
occurrences (all)	0	0	3
Pruritus			
subjects affected / exposed	2 / 44 (4.55%)	10 / 48 (20.83%)	22 / 52 (42.31%)
occurrences (all)	2	11	26
Rash			
subjects affected / exposed	4 / 44 (9.09%)	2 / 48 (4.17%)	7 / 52 (13.46%)
occurrences (all)	4	3	11
Rash macular			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Skin discolouration			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Rash maculo-papular			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	4 / 52 (7.69%)
occurrences (all)	2	1	7
Skin lesion			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Skin induration			

subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Skin ulcer			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	4 / 52 (7.69%)
occurrences (all)	1	3	4
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	2 / 52 (3.85%)
occurrences (all)	1	2	2
Dysuria			
subjects affected / exposed	0 / 44 (0.00%)	3 / 48 (6.25%)	4 / 52 (7.69%)
occurrences (all)	0	3	5
Haematuria			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	2	1	2
Micturition urgency			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Nocturia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Pollakiuria			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	3 / 52 (5.77%)
occurrences (all)	2	2	4
Urinary incontinence			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 44 (2.27%)	4 / 48 (8.33%)	10 / 52 (19.23%)
occurrences (all)	1	4	13
Back pain			

subjects affected / exposed	3 / 44 (6.82%)	7 / 48 (14.58%)	5 / 52 (9.62%)
occurrences (all)	3	7	6
Bone cyst			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Bursitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Bone pain			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	7 / 52 (13.46%)
occurrences (all)	3	1	7
Gouty arthritis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Groin pain			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	3	0	1
Joint swelling			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	7 / 52 (13.46%)
occurrences (all)	0	2	8
Muscular weakness			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	5 / 52 (9.62%)
occurrences (all)	1	1	6
Musculoskeletal chest pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	2 / 52 (3.85%)
occurrences (all)	0	0	2
Musculoskeletal pain			
subjects affected / exposed	2 / 44 (4.55%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal disorder			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Myalgia			

subjects affected / exposed	1 / 44 (2.27%)	3 / 48 (6.25%)	6 / 52 (11.54%)
occurrences (all)	1	3	8
Neck pain			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	3 / 44 (6.82%)	2 / 48 (4.17%)	7 / 52 (13.46%)
occurrences (all)	4	2	7
Pain in jaw			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Rhabdomyolysis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	4 / 52 (7.69%)
occurrences (all)	1	0	5
COVID-19			
subjects affected / exposed	0 / 44 (0.00%)	6 / 48 (12.50%)	6 / 52 (11.54%)
occurrences (all)	0	7	7
Cellulitis			
subjects affected / exposed	1 / 44 (2.27%)	2 / 48 (4.17%)	3 / 52 (5.77%)
occurrences (all)	1	3	5
Cystitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Eye infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Folliculitis			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	0	1	1
Fungal skin infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0

Gastroenteritis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	0 / 44 (0.00%)	4 / 48 (8.33%)	4 / 52 (7.69%)
occurrences (all)	0	4	4
Herpes simplex reactivation			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Hordeolum			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	1	1	1
Localised infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Oral herpes			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	3 / 52 (5.77%)
occurrences (all)	3	1	4
Orchitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Otitis media			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1

Pneumonia			
subjects affected / exposed	4 / 44 (9.09%)	2 / 48 (4.17%)	3 / 52 (5.77%)
occurrences (all)	4	2	3
Respiratory tract infection			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Septic shock			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	1 / 44 (2.27%)	3 / 48 (6.25%)	6 / 52 (11.54%)
occurrences (all)	1	3	6
Staphylococcal infection			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Skin infection			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	0 / 52 (0.00%)
occurrences (all)	0	2	0
Tooth infection			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	0	1	1
Urinary tract infection			
subjects affected / exposed	3 / 44 (6.82%)	5 / 48 (10.42%)	7 / 52 (13.46%)
occurrences (all)	3	6	9
Upper respiratory tract infection			
subjects affected / exposed	0 / 44 (0.00%)	2 / 48 (4.17%)	6 / 52 (11.54%)
occurrences (all)	0	2	17
Urinary tract infection bacterial			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Decreased appetite			

subjects affected / exposed	18 / 44 (40.91%)	7 / 48 (14.58%)	13 / 52 (25.00%)
occurrences (all)	20	9	17
Dehydration			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	1 / 52 (1.92%)
occurrences (all)	3	1	1
Folate deficiency			
subjects affected / exposed	0 / 44 (0.00%)	5 / 48 (10.42%)	0 / 52 (0.00%)
occurrences (all)	0	5	0
Gout			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	3 / 52 (5.77%)
occurrences (all)	0	1	3
Hypercholesterolaemia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	6 / 44 (13.64%)	1 / 48 (2.08%)	5 / 52 (9.62%)
occurrences (all)	7	1	7
Hyperkalaemia			
subjects affected / exposed	2 / 44 (4.55%)	5 / 48 (10.42%)	4 / 52 (7.69%)
occurrences (all)	3	18	5
Hypermagnesaemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	2	0	0
Hyperphosphataemia			
subjects affected / exposed	1 / 44 (2.27%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	1	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 44 (0.00%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	6 / 44 (13.64%)	5 / 48 (10.42%)	8 / 52 (15.38%)
occurrences (all)	7	10	11
Hypokalaemia			
subjects affected / exposed	2 / 44 (4.55%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	2	1	2
Hypocalcaemia			

subjects affected / exposed	2 / 44 (4.55%)	4 / 48 (8.33%)	2 / 52 (3.85%)
occurrences (all)	2	4	2
Hypomagnesaemia			
subjects affected / exposed	3 / 44 (6.82%)	4 / 48 (8.33%)	2 / 52 (3.85%)
occurrences (all)	3	5	3
Hypophosphataemia			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	0 / 52 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	4 / 44 (9.09%)	1 / 48 (2.08%)	2 / 52 (3.85%)
occurrences (all)	6	4	2
Iron overload			
subjects affected / exposed	0 / 44 (0.00%)	4 / 48 (8.33%)	0 / 52 (0.00%)
occurrences (all)	0	4	0
Tumour lysis syndrome			
subjects affected / exposed	1 / 44 (2.27%)	0 / 48 (0.00%)	1 / 52 (1.92%)
occurrences (all)	1	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 44 (0.00%)	1 / 48 (2.08%)	0 / 52 (0.00%)
occurrences (all)	0	1	0
Vitamin D deficiency			
subjects affected / exposed	0 / 44 (0.00%)	4 / 48 (8.33%)	0 / 52 (0.00%)
occurrences (all)	0	4	0

<b>Non-serious adverse events</b>	Phase 2 Arm 2 2A	Phase 2 Arm 2 2B	Phase 2 Arm 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	58 / 59 (98.31%)	28 / 28 (100.00%)	84 / 84 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	3 / 59 (5.08%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	3	0	3
Squamous cell carcinoma			
subjects affected / exposed	3 / 59 (5.08%)	1 / 28 (3.57%)	2 / 84 (2.38%)
occurrences (all)	3	1	2
Vascular disorders			

Flushing			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	0 / 84 (0.00%)
occurrences (all)	0	2	0
Haematoma			
subjects affected / exposed	1 / 59 (1.69%)	3 / 28 (10.71%)	4 / 84 (4.76%)
occurrences (all)	1	3	5
Hypertension			
subjects affected / exposed	3 / 59 (5.08%)	0 / 28 (0.00%)	6 / 84 (7.14%)
occurrences (all)	8	0	10
Hot flush			
subjects affected / exposed	1 / 59 (1.69%)	2 / 28 (7.14%)	1 / 84 (1.19%)
occurrences (all)	1	2	1
Hypotension			
subjects affected / exposed	3 / 59 (5.08%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	3	0	1
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	8 / 59 (13.56%)	3 / 28 (10.71%)	7 / 84 (8.33%)
occurrences (all)	15	4	11
Chills			
subjects affected / exposed	2 / 59 (3.39%)	6 / 28 (21.43%)	10 / 84 (11.90%)
occurrences (all)	2	9	11
Early satiety			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	5 / 84 (5.95%)
occurrences (all)	0	0	5
Fatigue			
subjects affected / exposed	13 / 59 (22.03%)	13 / 28 (46.43%)	27 / 84 (32.14%)
occurrences (all)	17	15	44
Gait disturbance			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	1 / 84 (1.19%)
occurrences (all)	0	2	1
Malaise			

subjects affected / exposed	2 / 59 (3.39%)	2 / 28 (7.14%)	3 / 84 (3.57%)
occurrences (all)	2	2	3
Influenza like illness			
subjects affected / exposed	0 / 59 (0.00%)	3 / 28 (10.71%)	4 / 84 (4.76%)
occurrences (all)	0	7	6
Mucosal inflammation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	2
Nodule			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Non-cardiac chest pain			
subjects affected / exposed	1 / 59 (1.69%)	5 / 28 (17.86%)	5 / 84 (5.95%)
occurrences (all)	2	5	8
Oedema peripheral			
subjects affected / exposed	12 / 59 (20.34%)	6 / 28 (21.43%)	12 / 84 (14.29%)
occurrences (all)	15	7	12
Pain			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	2	0	3
Pyrexia			
subjects affected / exposed	8 / 59 (13.56%)	6 / 28 (21.43%)	14 / 84 (16.67%)
occurrences (all)	9	9	17
Peripheral swelling			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Genital lesion			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	13 / 59 (22.03%)	14 / 28 (50.00%)	22 / 84 (26.19%)
occurrences (all)	19	21	25
Dyspnoea			
subjects affected / exposed	9 / 59 (15.25%)	7 / 28 (25.00%)	20 / 84 (23.81%)
occurrences (all)	11	7	21
Dyspnoea exertional			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	5 / 84 (5.95%)
occurrences (all)	2	0	5
Epistaxis			
subjects affected / exposed	10 / 59 (16.95%)	9 / 28 (32.14%)	13 / 84 (15.48%)
occurrences (all)	33	12	37
Hypoxia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	2 / 59 (3.39%)	2 / 28 (7.14%)	3 / 84 (3.57%)
occurrences (all)	2	2	4
Oropharyngeal pain			
subjects affected / exposed	6 / 59 (10.17%)	5 / 28 (17.86%)	9 / 84 (10.71%)
occurrences (all)	8	6	12
Pleural effusion			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	2	0	2
Productive cough			
subjects affected / exposed	3 / 59 (5.08%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences (all)	4	1	3
Rhinorrhoea			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	4 / 84 (4.76%)
occurrences (all)	0	2	4
Pulmonary oedema			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Sinus pain			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	0	1	0

Upper-airway cough syndrome subjects affected / exposed occurrences (all)	6 / 59 (10.17%) 6	1 / 28 (3.57%) 1	3 / 84 (3.57%) 3
Wheezing subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	1 / 84 (1.19%) 1
Psychiatric disorders			
Confusional state subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	2 / 84 (2.38%) 2
Anxiety subjects affected / exposed occurrences (all)	3 / 59 (5.08%) 3	1 / 28 (3.57%) 1	4 / 84 (4.76%) 4
Delirium subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	1 / 84 (1.19%) 1
Insomnia subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 5	3 / 28 (10.71%) 3	7 / 84 (8.33%) 7
Depression subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 2	3 / 28 (10.71%) 3	2 / 84 (2.38%) 2
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 10	6 / 28 (21.43%) 6	8 / 84 (9.52%) 10
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 10	5 / 28 (17.86%) 5	6 / 84 (7.14%) 7
Blast cell count increased subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	2 / 28 (7.14%) 2	2 / 84 (2.38%) 2
Bilirubin conjugated increased			

subjects affected / exposed	2 / 59 (3.39%)	2 / 28 (7.14%)	1 / 84 (1.19%)
occurrences (all)	2	3	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 59 (0.00%)	3 / 28 (10.71%)	5 / 84 (5.95%)
occurrences (all)	0	3	5
Blood bilirubin increased			
subjects affected / exposed	5 / 59 (8.47%)	4 / 28 (14.29%)	5 / 84 (5.95%)
occurrences (all)	5	4	8
Blood creatinine increased			
subjects affected / exposed	5 / 59 (8.47%)	1 / 28 (3.57%)	11 / 84 (13.10%)
occurrences (all)	6	1	15
Blood phosphorus increased			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Blood uric acid increased			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	2	0	0
Cardiac murmur			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	0 / 84 (0.00%)
occurrences (all)	0	3	0
Ejection fraction decreased			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Electrocardiogram QRS complex abnormal			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Haematocrit increased			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			

subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	2 / 84 (2.38%) 2
Lymphocyte count decreased subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 6	0 / 28 (0.00%) 0	1 / 84 (1.19%) 1
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	4 / 84 (4.76%) 12
Platelet count decreased subjects affected / exposed occurrences (all)	11 / 59 (18.64%) 22	8 / 28 (28.57%) 13	22 / 84 (26.19%) 37
Transaminases increased subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Troponin T increased subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	8 / 59 (13.56%) 8	2 / 28 (7.14%) 2	2 / 84 (2.38%) 2
Weight increased subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	4 / 84 (4.76%) 4
White blood cell count decreased subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 5	0 / 28 (0.00%) 0	4 / 84 (4.76%) 10
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	9 / 59 (15.25%) 11	8 / 28 (28.57%) 11	16 / 84 (19.05%) 21
Fall subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 4	7 / 28 (25.00%) 10	9 / 84 (10.71%) 15
Nail injury			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 59 (1.69%)	2 / 28 (7.14%)	1 / 84 (1.19%)
occurrences (all)	1	2	1
Procedural site reaction			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	2	0	1
Vascular access site complication			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	2 / 59 (3.39%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	2	1	1
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	3 / 84 (3.57%)
occurrences (all)	0	0	3
Angina pectoris			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Atrioventricular block			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Hyperdynamic left ventricle			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	2 / 59 (3.39%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences (all)	2	2	9
Sinus tachycardia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0

Tachycardia subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	2 / 84 (2.38%) 2
Nervous system disorders			
Ageusia subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Cerebrovascular accident subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	13 / 59 (22.03%) 16	5 / 28 (17.86%) 6	21 / 84 (25.00%) 30
Dysgeusia subjects affected / exposed occurrences (all)	16 / 59 (27.12%) 23	7 / 28 (25.00%) 7	21 / 84 (25.00%) 23
Dysarthria subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 2	0 / 28 (0.00%) 0	1 / 84 (1.19%) 1
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	2 / 28 (7.14%) 2	2 / 84 (2.38%) 5
Headache subjects affected / exposed occurrences (all)	6 / 59 (10.17%) 6	3 / 28 (10.71%) 6	19 / 84 (22.62%) 24
Lethargy subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	1 / 28 (3.57%) 2	1 / 84 (1.19%) 2
Memory impairment subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	2 / 28 (7.14%) 2	0 / 84 (0.00%) 0
Myoclonus subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Migraine			

subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	4 / 84 (4.76%)
occurrences (all)	0	0	4
Neuropathy peripheral			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	2 / 84 (2.38%)
occurrences (all)	1	1	2
Paraesthesia			
subjects affected / exposed	5 / 59 (8.47%)	4 / 28 (14.29%)	4 / 84 (4.76%)
occurrences (all)	7	4	7
Presyncope			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	4 / 84 (4.76%)
occurrences (all)	0	0	4
Sciatica			
subjects affected / exposed	3 / 59 (5.08%)	1 / 28 (3.57%)	4 / 84 (4.76%)
occurrences (all)	7	1	6
Syncope			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences (all)	0	2	3
Taste disorder			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	0	0	2
Blood and lymphatic system disorders			
Leukocytosis			
subjects affected / exposed	1 / 59 (1.69%)	2 / 28 (7.14%)	4 / 84 (4.76%)
occurrences (all)	1	2	4
Anaemia			
subjects affected / exposed	18 / 59 (30.51%)	7 / 28 (25.00%)	41 / 84 (48.81%)
occurrences (all)	23	16	76
Lymphadenopathy			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	2	0	3
Neutropenia			
subjects affected / exposed	10 / 59 (16.95%)	1 / 28 (3.57%)	2 / 84 (2.38%)
occurrences (all)	17	2	3
Spleen disorder			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	2	0	0

Thrombocytopenia subjects affected / exposed occurrences (all)	25 / 59 (42.37%) 55	9 / 28 (32.14%) 21	32 / 84 (38.10%) 53
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Ear and labyrinth disorders			
Ear discomfort subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	2 / 84 (2.38%) 2
Ear haemorrhage subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 28 (3.57%) 1	0 / 84 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	1 / 28 (3.57%) 1	2 / 84 (2.38%) 2
Hypoacusis subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	1 / 84 (1.19%) 1
Tinnitus subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 2	0 / 28 (0.00%) 0	6 / 84 (7.14%) 8
Eye disorders			
Eye haemorrhage subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Vision blurred subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 3	1 / 28 (3.57%) 1	3 / 84 (3.57%) 3
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	5 / 59 (8.47%) 6	1 / 28 (3.57%) 1	4 / 84 (4.76%) 4
Abdominal distension subjects affected / exposed occurrences (all)	6 / 59 (10.17%) 7	8 / 28 (28.57%) 12	13 / 84 (15.48%) 14
Abdominal pain			

subjects affected / exposed	4 / 59 (6.78%)	7 / 28 (25.00%)	13 / 84 (15.48%)
occurrences (all)	6	9	17
Abdominal pain upper			
subjects affected / exposed	4 / 59 (6.78%)	4 / 28 (14.29%)	11 / 84 (13.10%)
occurrences (all)	5	5	18
Anal incontinence			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	9 / 59 (15.25%)	6 / 28 (21.43%)	27 / 84 (32.14%)
occurrences (all)	11	7	29
Diarrhoea			
subjects affected / exposed	34 / 59 (57.63%)	18 / 28 (64.29%)	40 / 84 (47.62%)
occurrences (all)	65	34	71
Dry mouth			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences (all)	0	1	3
Dyspepsia			
subjects affected / exposed	2 / 59 (3.39%)	1 / 28 (3.57%)	4 / 84 (4.76%)
occurrences (all)	3	1	5
Dysphagia			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	1	1	1
Enterocolitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	7 / 84 (8.33%)
occurrences (all)	1	0	7
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Gingival bleeding			

subjects affected / exposed	3 / 59 (5.08%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	4	0	2
Gingival pain			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	2
Haemorrhoids			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	5 / 84 (5.95%)
occurrences (all)	0	0	6
Melaena			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	1	1	1
Mouth haemorrhage			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	1	0	1
Mouth ulceration			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	5 / 84 (5.95%)
occurrences (all)	1	0	6
Nausea			
subjects affected / exposed	21 / 59 (35.59%)	12 / 28 (42.86%)	26 / 84 (30.95%)
occurrences (all)	31	18	39
Stomatitis			
subjects affected / exposed	5 / 59 (8.47%)	3 / 28 (10.71%)	3 / 84 (3.57%)
occurrences (all)	5	3	3
Oral disorder			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Proctalgia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	10 / 59 (16.95%)	8 / 28 (28.57%)	15 / 84 (17.86%)
occurrences (all)	14	9	18
Hepatobiliary disorders			

Hyperbilirubinaemia subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 4	0 / 28 (0.00%) 0	2 / 84 (2.38%) 6
Skin and subcutaneous tissue disorders			
Dermatitis acneiform subjects affected / exposed occurrences (all)	3 / 59 (5.08%) 5	0 / 28 (0.00%) 0	3 / 84 (3.57%) 3
Dry skin subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	4 / 84 (4.76%) 4
Erythema subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 28 (3.57%) 1	1 / 84 (1.19%) 1
Hyperhidrosis subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 2	0 / 28 (0.00%) 0	2 / 84 (2.38%) 3
Night sweats subjects affected / exposed occurrences (all)	6 / 59 (10.17%) 8	2 / 28 (7.14%) 3	12 / 84 (14.29%) 18
Petechiae subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	1 / 84 (1.19%) 1
Pruritus subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 2	7 / 28 (25.00%) 9	18 / 84 (21.43%) 21
Rash subjects affected / exposed occurrences (all)	3 / 59 (5.08%) 3	4 / 28 (14.29%) 5	6 / 84 (7.14%) 8
Rash macular subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Skin discolouration subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	1 / 28 (3.57%) 1	0 / 84 (0.00%) 0
Rash maculo-papular			

subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	4 / 84 (4.76%)
occurrences (all)	0	2	7
Skin lesion			
subjects affected / exposed	2 / 59 (3.39%)	2 / 28 (7.14%)	5 / 84 (5.95%)
occurrences (all)	2	2	5
Skin induration			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	2	0	2
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	1	1	0
Dysuria			
subjects affected / exposed	5 / 59 (8.47%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	6	0	3
Haematuria			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	3 / 84 (3.57%)
occurrences (all)	2	0	3
Micturition urgency			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	1	0	0
Nocturia			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	2 / 84 (2.38%)
occurrences (all)	0	2	2
Pollakiuria			
subjects affected / exposed	1 / 59 (1.69%)	2 / 28 (7.14%)	4 / 84 (4.76%)
occurrences (all)	1	2	4
Urinary incontinence			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	11 / 59 (18.64%)	7 / 28 (25.00%)	21 / 84 (25.00%)
occurrences (all)	12	8	26
Back pain			
subjects affected / exposed	8 / 59 (13.56%)	4 / 28 (14.29%)	17 / 84 (20.24%)
occurrences (all)	9	4	23
Bone cyst			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	0	1	1
Bone pain			
subjects affected / exposed	8 / 59 (13.56%)	2 / 28 (7.14%)	8 / 84 (9.52%)
occurrences (all)	10	2	10
Gouty arthritis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	2 / 84 (2.38%)
occurrences (all)	1	1	2
Joint swelling			
subjects affected / exposed	2 / 59 (3.39%)	2 / 28 (7.14%)	1 / 84 (1.19%)
occurrences (all)	3	2	1
Muscle spasms			
subjects affected / exposed	7 / 59 (11.86%)	10 / 28 (35.71%)	18 / 84 (21.43%)
occurrences (all)	7	11	24
Muscular weakness			
subjects affected / exposed	7 / 59 (11.86%)	1 / 28 (3.57%)	5 / 84 (5.95%)
occurrences (all)	9	1	7
Musculoskeletal chest pain			
subjects affected / exposed	3 / 59 (5.08%)	0 / 28 (0.00%)	6 / 84 (7.14%)
occurrences (all)	3	0	7
Musculoskeletal pain			

subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	4 / 84 (4.76%)
occurrences (all)	2	0	4
Musculoskeletal disorder			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	5 / 59 (8.47%)	3 / 28 (10.71%)	10 / 84 (11.90%)
occurrences (all)	7	5	12
Neck pain			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	6 / 84 (7.14%)
occurrences (all)	1	0	6
Pain in extremity			
subjects affected / exposed	8 / 59 (13.56%)	9 / 28 (32.14%)	15 / 84 (17.86%)
occurrences (all)	11	10	20
Pain in jaw			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Rhabdomyolysis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 59 (0.00%)	3 / 28 (10.71%)	3 / 84 (3.57%)
occurrences (all)	0	3	3
COVID-19			
subjects affected / exposed	9 / 59 (15.25%)	3 / 28 (10.71%)	24 / 84 (28.57%)
occurrences (all)	10	3	29
Cellulitis			
subjects affected / exposed	2 / 59 (3.39%)	2 / 28 (7.14%)	2 / 84 (2.38%)
occurrences (all)	2	2	3
Cystitis			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	2	0	1
Eye infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	0	0	2

Folliculitis			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	4	0	3
Fungal skin infection			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	1	0	2
Herpes zoster			
subjects affected / exposed	4 / 59 (6.78%)	4 / 28 (14.29%)	14 / 84 (16.67%)
occurrences (all)	6	4	15
Herpes simplex reactivation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	5 / 84 (5.95%)
occurrences (all)	0	0	7
Hordeolum			
subjects affected / exposed	2 / 59 (3.39%)	0 / 28 (0.00%)	4 / 84 (4.76%)
occurrences (all)	2	0	8
Localised infection			
subjects affected / exposed	3 / 59 (5.08%)	0 / 28 (0.00%)	1 / 84 (1.19%)
occurrences (all)	3	0	1
Lower respiratory tract infection			
subjects affected / exposed	2 / 59 (3.39%)	3 / 28 (10.71%)	2 / 84 (2.38%)
occurrences (all)	3	5	2
Oral herpes			
subjects affected / exposed	5 / 59 (8.47%)	4 / 28 (14.29%)	2 / 84 (2.38%)
occurrences (all)	6	8	3
Nasopharyngitis			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	10 / 84 (11.90%)
occurrences (all)	0	2	17
Orchitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0

Otitis media			
subjects affected / exposed	2 / 59 (3.39%)	1 / 28 (3.57%)	0 / 84 (0.00%)
occurrences (all)	2	1	0
Pharyngitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	5 / 59 (8.47%)	3 / 28 (10.71%)	8 / 84 (9.52%)
occurrences (all)	6	5	8
Respiratory tract infection			
subjects affected / exposed	1 / 59 (1.69%)	0 / 28 (0.00%)	5 / 84 (5.95%)
occurrences (all)	1	0	6
Rhinitis			
subjects affected / exposed	1 / 59 (1.69%)	1 / 28 (3.57%)	3 / 84 (3.57%)
occurrences (all)	1	1	3
Septic shock			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	2 / 59 (3.39%)	1 / 28 (3.57%)	4 / 84 (4.76%)
occurrences (all)	4	1	7
Staphylococcal infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	2 / 84 (2.38%)
occurrences (all)	0	2	2
Tooth infection			
subjects affected / exposed	0 / 59 (0.00%)	2 / 28 (7.14%)	4 / 84 (4.76%)
occurrences (all)	0	2	5
Urinary tract infection			
subjects affected / exposed	6 / 59 (10.17%)	3 / 28 (10.71%)	14 / 84 (16.67%)
occurrences (all)	10	11	26
Upper respiratory tract infection			
subjects affected / exposed	11 / 59 (18.64%)	8 / 28 (28.57%)	14 / 84 (16.67%)
occurrences (all)	19	14	17

Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	13 / 59 (22.03%) 13	7 / 28 (25.00%) 7	15 / 84 (17.86%) 20
Dehydration subjects affected / exposed occurrences (all)	3 / 59 (5.08%) 3	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Folate deficiency subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Gout subjects affected / exposed occurrences (all)	2 / 59 (3.39%) 2	1 / 28 (3.57%) 1	2 / 84 (2.38%) 2
Hypercholesterolaemia subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	2 / 28 (7.14%) 2	3 / 84 (3.57%) 3
Hyperglycaemia subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 5	2 / 28 (7.14%) 2	1 / 84 (1.19%) 1
Hyperkalaemia subjects affected / exposed occurrences (all)	4 / 59 (6.78%) 7	2 / 28 (7.14%) 9	6 / 84 (7.14%) 9
Hypermagnesaemia subjects affected / exposed occurrences (all)	0 / 59 (0.00%) 0	0 / 28 (0.00%) 0	0 / 84 (0.00%) 0
Hyperphosphataemia subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	2 / 84 (2.38%) 7
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	1 / 59 (1.69%) 1	0 / 28 (0.00%) 0	5 / 84 (5.95%) 12
Hyperuricaemia			

subjects affected / exposed	5 / 59 (8.47%)	4 / 28 (14.29%)	5 / 84 (5.95%)
occurrences (all)	5	4	6
Hypokalaemia			
subjects affected / exposed	4 / 59 (6.78%)	1 / 28 (3.57%)	4 / 84 (4.76%)
occurrences (all)	4	1	4
Hypocalcaemia			
subjects affected / exposed	3 / 59 (5.08%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	6	1	1
Hypomagnesaemia			
subjects affected / exposed	2 / 59 (3.39%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	4	2	1
Hypophosphataemia			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	0	3	1
Hyponatraemia			
subjects affected / exposed	3 / 59 (5.08%)	2 / 28 (7.14%)	11 / 84 (13.10%)
occurrences (all)	3	2	13
Iron overload			
subjects affected / exposed	4 / 59 (6.78%)	0 / 28 (0.00%)	2 / 84 (2.38%)
occurrences (all)	4	0	2
Tumour lysis syndrome			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 59 (0.00%)	0 / 28 (0.00%)	0 / 84 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 59 (0.00%)	1 / 28 (3.57%)	1 / 84 (1.19%)
occurrences (all)	0	1	1

<b>Non-serious adverse events</b>	Phase 2 Arm 4	Phase 2 Overall	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 21 (100.00%)	289 / 292 (98.97%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	5 / 292 (1.71%) 9	
Squamous cell carcinoma subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 2	8 / 292 (2.74%) 9	
Vascular disorders			
Flushing subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	4 / 292 (1.37%) 4	
Haematoma subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	12 / 292 (4.11%) 13	
Hypertension subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 3	16 / 292 (5.48%) 27	
Hot flush subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	6 / 292 (2.05%) 6	
Hypotension subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	7 / 292 (2.40%) 7	
General disorders and administration site conditions			
Chest pain subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	4 / 292 (1.37%) 4	
Asthenia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	30 / 292 (10.27%) 42	
Chills subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	21 / 292 (7.19%) 25	
Early satiety subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	11 / 292 (3.77%) 13	
Fatigue			

subjects affected / exposed	5 / 21 (23.81%)	89 / 292 (30.48%)	
occurrences (all)	11	124	
Gait disturbance			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Malaise			
subjects affected / exposed	0 / 21 (0.00%)	10 / 292 (3.42%)	
occurrences (all)	0	10	
Influenza like illness			
subjects affected / exposed	1 / 21 (4.76%)	13 / 292 (4.45%)	
occurrences (all)	2	22	
Mucosal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences (all)	0	2	
Nodule			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Non-cardiac chest pain			
subjects affected / exposed	2 / 21 (9.52%)	16 / 292 (5.48%)	
occurrences (all)	3	22	
Oedema peripheral			
subjects affected / exposed	0 / 21 (0.00%)	51 / 292 (17.47%)	
occurrences (all)	0	58	
Pain			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences (all)	0	6	
Pyrexia			
subjects affected / exposed	2 / 21 (9.52%)	44 / 292 (15.07%)	
occurrences (all)	3	56	
Peripheral swelling			
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)	
occurrences (all)	0	5	
Reproductive system and breast disorders			
Genital lesion			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Vaginal haemorrhage			
subjects affected / exposed	1 / 21 (4.76%)	4 / 292 (1.37%)	
occurrences (all)	1	4	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 21 (19.05%)	73 / 292 (25.00%)	
occurrences (all)	7	99	
Dyspnoea			
subjects affected / exposed	1 / 21 (4.76%)	58 / 292 (19.86%)	
occurrences (all)	1	66	
Dyspnoea exertional			
subjects affected / exposed	0 / 21 (0.00%)	8 / 292 (2.74%)	
occurrences (all)	0	8	
Epistaxis			
subjects affected / exposed	2 / 21 (9.52%)	47 / 292 (16.10%)	
occurrences (all)	3	109	
Hypoxia			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Nasal congestion			
subjects affected / exposed	1 / 21 (4.76%)	10 / 292 (3.42%)	
occurrences (all)	1	11	
Oropharyngeal pain			
subjects affected / exposed	2 / 21 (9.52%)	26 / 292 (8.90%)	
occurrences (all)	2	32	
Pleural effusion			
subjects affected / exposed	0 / 21 (0.00%)	7 / 292 (2.40%)	
occurrences (all)	0	7	
Productive cough			
subjects affected / exposed	0 / 21 (0.00%)	12 / 292 (4.11%)	
occurrences (all)	0	13	
Rhinorrhoea			

subjects affected / exposed	3 / 21 (14.29%)	13 / 292 (4.45%)	
occurrences (all)	3	13	
Pulmonary oedema			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Sinus pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences (all)	0	1	
Upper-airway cough syndrome			
subjects affected / exposed	1 / 21 (4.76%)	15 / 292 (5.14%)	
occurrences (all)	1	15	
Wheezing			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 21 (4.76%)	7 / 292 (2.40%)	
occurrences (all)	1	7	
Anxiety			
subjects affected / exposed	0 / 21 (0.00%)	9 / 292 (3.08%)	
occurrences (all)	0	9	
Delirium			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Insomnia			
subjects affected / exposed	2 / 21 (9.52%)	22 / 292 (7.53%)	
occurrences (all)	2	23	
Depression			
subjects affected / exposed	0 / 21 (0.00%)	8 / 292 (2.74%)	
occurrences (all)	0	9	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	24 / 292 (8.22%)	
occurrences (all)	0	31	
Activated partial thromboplastin time prolonged			

subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)
occurrences (all)	0	2
Aspartate aminotransferase increased		
subjects affected / exposed	1 / 21 (4.76%)	24 / 292 (8.22%)
occurrences (all)	1	30
Blast cell count increased		
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)
occurrences (all)	0	5
Bilirubin conjugated increased		
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)
occurrences (all)	0	7
Blood alkaline phosphatase increased		
subjects affected / exposed	0 / 21 (0.00%)	13 / 292 (4.45%)
occurrences (all)	0	14
Blood bilirubin increased		
subjects affected / exposed	2 / 21 (9.52%)	20 / 292 (6.85%)
occurrences (all)	4	25
Blood creatinine increased		
subjects affected / exposed	1 / 21 (4.76%)	25 / 292 (8.56%)
occurrences (all)	1	31
Blood phosphorus increased		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	1
Blood uric acid increased		
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)
occurrences (all)	0	3
Cardiac murmur		
subjects affected / exposed	1 / 21 (4.76%)	5 / 292 (1.71%)
occurrences (all)	1	6
Ejection fraction decreased		
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)
occurrences (all)	0	2
Electrocardiogram QRS complex abnormal		

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Electrocardiogram QT prolonged		
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)
occurrences (all)	0	2
Haematocrit increased		
subjects affected / exposed	2 / 21 (9.52%)	2 / 292 (0.68%)
occurrences (all)	8	8
International normalised ratio increased		
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)
occurrences (all)	0	5
Lymphocyte count decreased		
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)
occurrences (all)	0	9
Neutrophil count decreased		
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)
occurrences (all)	0	13
Platelet count decreased		
subjects affected / exposed	2 / 21 (9.52%)	56 / 292 (19.18%)
occurrences (all)	2	94
Transaminases increased		
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Troponin T increased		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	1
Weight decreased		
subjects affected / exposed	4 / 21 (19.05%)	39 / 292 (13.36%)
occurrences (all)	4	41
Weight increased		
subjects affected / exposed	0 / 21 (0.00%)	8 / 292 (2.74%)
occurrences (all)	0	9
White blood cell count decreased		
subjects affected / exposed	0 / 21 (0.00%)	10 / 292 (3.42%)
occurrences (all)	0	17

Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	2 / 21 (9.52%)	48 / 292 (16.44%)	
occurrences (all)	4	62	
Fall			
subjects affected / exposed	0 / 21 (0.00%)	33 / 292 (11.30%)	
occurrences (all)	0	44	
Nail injury			
subjects affected / exposed	2 / 21 (9.52%)	2 / 292 (0.68%)	
occurrences (all)	3	3	
Procedural pain			
subjects affected / exposed	1 / 21 (4.76%)	6 / 292 (2.05%)	
occurrences (all)	1	6	
Procedural site reaction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Skin laceration			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences (all)	0	6	
Vascular access site complication			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Wound			
subjects affected / exposed	0 / 21 (0.00%)	7 / 292 (2.40%)	
occurrences (all)	0	7	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 21 (0.00%)	7 / 292 (2.40%)	
occurrences (all)	0	8	
Angina pectoris			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Atrioventricular block			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Hyperdynamic left ventricle			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Palpitations			
subjects affected / exposed	3 / 21 (14.29%)	14 / 292 (4.79%)	
occurrences (all)	5	23	
Sinus tachycardia			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	4	
Tachycardia			
subjects affected / exposed	1 / 21 (4.76%)	6 / 292 (2.05%)	
occurrences (all)	1	6	
Nervous system disorders			
Ageusia			
subjects affected / exposed	6 / 21 (28.57%)	7 / 292 (2.40%)	
occurrences (all)	7	8	
Cerebrovascular accident			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Dizziness			
subjects affected / exposed	4 / 21 (19.05%)	60 / 292 (20.55%)	
occurrences (all)	4	78	
Dysgeusia			
subjects affected / exposed	9 / 21 (42.86%)	79 / 292 (27.05%)	
occurrences (all)	12	95	
Dysarthria			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences (all)	0	3	
Hypoaesthesia			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences (all)	0	9	
Headache			
subjects affected / exposed	6 / 21 (28.57%)	54 / 292 (18.49%)	
occurrences (all)	11	79	
Lethargy			
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)	
occurrences (all)	0	6	

Memory impairment subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	3 / 292 (1.03%) 3	
Myoclonus subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 292 (0.00%) 0	
Migraine subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	8 / 292 (2.74%) 8	
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	7 / 292 (2.40%) 7	
Paraesthesia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	17 / 292 (5.82%) 22	
Presyncope subjects affected / exposed occurrences (all)	3 / 21 (14.29%) 3	7 / 292 (2.40%) 7	
Sciatica subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	8 / 292 (2.74%) 14	
Syncope subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	5 / 292 (1.71%) 6	
Taste disorder subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 3	7 / 292 (2.40%) 9	
Blood and lymphatic system disorders			
Leukocytosis subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 3	11 / 292 (3.77%) 13	
Anaemia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	99 / 292 (33.90%) 163	
Lymphadenopathy			

subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)	
occurrences (all)	0	5	
Neutropenia			
subjects affected / exposed	1 / 21 (4.76%)	16 / 292 (5.48%)	
occurrences (all)	1	25	
Spleen disorder			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences (all)	0	6	
Thrombocytopenia			
subjects affected / exposed	0 / 21 (0.00%)	96 / 292 (32.88%)	
occurrences (all)	0	179	
Thrombocytosis			
subjects affected / exposed	1 / 21 (4.76%)	5 / 292 (1.71%)	
occurrences (all)	8	12	
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences (all)	0	2	
Ear haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences (all)	0	1	
Ear pain			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences (all)	0	6	
Hypoacusis			
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)	
occurrences (all)	0	3	
Tinnitus			
subjects affected / exposed	1 / 21 (4.76%)	12 / 292 (4.11%)	
occurrences (all)	1	14	
Eye disorders			
Eye haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences (all)	0	2	
Vision blurred			

subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	9 / 292 (3.08%) 10	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 21 (0.00%)	18 / 292 (6.16%)	
occurrences (all)	0	20	
Abdominal distension			
subjects affected / exposed	1 / 21 (4.76%)	44 / 292 (15.07%)	
occurrences (all)	1	55	
Abdominal pain			
subjects affected / exposed	6 / 21 (28.57%)	52 / 292 (17.81%)	
occurrences (all)	7	65	
Abdominal pain upper			
subjects affected / exposed	3 / 21 (14.29%)	30 / 292 (10.27%)	
occurrences (all)	3	40	
Anal incontinence			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences (all)	0	1	
Constipation			
subjects affected / exposed	10 / 21 (47.62%)	77 / 292 (26.37%)	
occurrences (all)	13	89	
Diarrhoea			
subjects affected / exposed	10 / 21 (47.62%)	143 / 292 (48.97%)	
occurrences (all)	18	260	
Dry mouth			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences (all)	0	5	
Dyspepsia			
subjects affected / exposed	1 / 21 (4.76%)	10 / 292 (3.42%)	
occurrences (all)	1	12	
Dysphagia			
subjects affected / exposed	1 / 21 (4.76%)	4 / 292 (1.37%)	
occurrences (all)	1	4	
Enterocolitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	

Eructation		
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Flatulence		
subjects affected / exposed	1 / 21 (4.76%)	13 / 292 (4.45%)
occurrences (all)	1	13
Gastrooesophageal reflux disease		
subjects affected / exposed	1 / 21 (4.76%)	6 / 292 (2.05%)
occurrences (all)	1	6
Gingival bleeding		
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)
occurrences (all)	0	8
Gingival pain		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	1
Haemorrhoidal haemorrhage		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	2
Haemorrhoids		
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)
occurrences (all)	0	6
Melaena		
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)
occurrences (all)	0	3
Mouth haemorrhage		
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)
occurrences (all)	0	2
Mouth ulceration		
subjects affected / exposed	1 / 21 (4.76%)	9 / 292 (3.08%)
occurrences (all)	1	11
Nausea		
subjects affected / exposed	16 / 21 (76.19%)	116 / 292 (39.73%)
occurrences (all)	28	174
Stomatitis		
subjects affected / exposed	0 / 21 (0.00%)	14 / 292 (4.79%)
occurrences (all)	0	14

Oral disorder			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences (all)	0	1	
Proctalgia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	9 / 21 (42.86%)	59 / 292 (20.21%)	
occurrences (all)	15	81	
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	0 / 21 (0.00%)	9 / 292 (3.08%)	
occurrences (all)	0	21	
Skin and subcutaneous tissue disorders			
Dermatitis acneiform			
subjects affected / exposed	1 / 21 (4.76%)	10 / 292 (3.42%)	
occurrences (all)	1	14	
Dry skin			
subjects affected / exposed	0 / 21 (0.00%)	7 / 292 (2.40%)	
occurrences (all)	0	7	
Erythema			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences (all)	0	6	
Hyperhidrosis			
subjects affected / exposed	1 / 21 (4.76%)	10 / 292 (3.42%)	
occurrences (all)	1	12	
Night sweats			
subjects affected / exposed	0 / 21 (0.00%)	32 / 292 (10.96%)	
occurrences (all)	0	44	
Petechiae			
subjects affected / exposed	1 / 21 (4.76%)	6 / 292 (2.05%)	
occurrences (all)	1	6	
Pruritus			
subjects affected / exposed	3 / 21 (14.29%)	62 / 292 (21.23%)	
occurrences (all)	3	72	
Rash			

subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 5	26 / 292 (8.90%) 35	
Rash macular subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	2 / 292 (0.68%) 2	
Skin discolouration subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 292 (0.34%) 1	
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	10 / 292 (3.42%) 17	
Skin lesion subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 5	15 / 292 (5.14%) 16	
Skin induration subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 292 (0.00%) 0	
Urticaria subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 292 (0.34%) 1	
Skin ulcer subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	9 / 292 (3.08%) 11	
Renal and urinary disorders			
Acute kidney injury subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	6 / 292 (2.05%) 6	
Dysuria subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	15 / 292 (5.14%) 18	
Haematuria subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	9 / 292 (3.08%) 10	
Micturition urgency subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 292 (0.34%) 1	

Nocturia			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences (all)	0	5	
Pollakiuria			
subjects affected / exposed	1 / 21 (4.76%)	13 / 292 (4.45%)	
occurrences (all)	1	14	
Urinary incontinence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 21 (14.29%)	56 / 292 (19.18%)	
occurrences (all)	6	69	
Back pain			
subjects affected / exposed	3 / 21 (14.29%)	44 / 292 (15.07%)	
occurrences (all)	3	52	
Bone cyst			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Bursitis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)	
occurrences (all)	0	2	
Bone pain			
subjects affected / exposed	2 / 21 (9.52%)	28 / 292 (9.59%)	
occurrences (all)	2	32	
Gouty arthritis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Groin pain			
subjects affected / exposed	0 / 21 (0.00%)	5 / 292 (1.71%)	
occurrences (all)	0	5	
Joint swelling			
subjects affected / exposed	2 / 21 (9.52%)	8 / 292 (2.74%)	
occurrences (all)	2	9	
Muscle spasms			

subjects affected / exposed	6 / 21 (28.57%)	50 / 292 (17.12%)	
occurrences (all)	9	61	
Muscular weakness			
subjects affected / exposed	1 / 21 (4.76%)	20 / 292 (6.85%)	
occurrences (all)	1	25	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 21 (4.76%)	12 / 292 (4.11%)	
occurrences (all)	1	13	
Musculoskeletal pain			
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)	
occurrences (all)	0	6	
Musculoskeletal disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	3 / 21 (14.29%)	30 / 292 (10.27%)	
occurrences (all)	3	38	
Neck pain			
subjects affected / exposed	0 / 21 (0.00%)	8 / 292 (2.74%)	
occurrences (all)	0	8	
Pain in extremity			
subjects affected / exposed	0 / 21 (0.00%)	41 / 292 (14.04%)	
occurrences (all)	0	50	
Pain in jaw			
subjects affected / exposed	1 / 21 (4.76%)	2 / 292 (0.68%)	
occurrences (all)	1	2	
Rhabdomyolysis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 21 (4.76%)	11 / 292 (3.77%)	
occurrences (all)	1	12	
COVID-19			
subjects affected / exposed	4 / 21 (19.05%)	52 / 292 (17.81%)	
occurrences (all)	4	60	

Cellulitis		
subjects affected / exposed	1 / 21 (4.76%)	12 / 292 (4.11%)
occurrences (all)	1	16
Cystitis		
subjects affected / exposed	2 / 21 (9.52%)	6 / 292 (2.05%)
occurrences (all)	4	8
Eye infection		
subjects affected / exposed	0 / 21 (0.00%)	2 / 292 (0.68%)
occurrences (all)	0	2
Folliculitis		
subjects affected / exposed	2 / 21 (9.52%)	8 / 292 (2.74%)
occurrences (all)	4	13
Fungal skin infection		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	1
Gastroenteritis		
subjects affected / exposed	4 / 21 (19.05%)	8 / 292 (2.74%)
occurrences (all)	5	9
Herpes zoster		
subjects affected / exposed	1 / 21 (4.76%)	31 / 292 (10.62%)
occurrences (all)	1	34
Herpes simplex reactivation		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)
occurrences (all)	0	8
Hordeolum		
subjects affected / exposed	0 / 21 (0.00%)	8 / 292 (2.74%)
occurrences (all)	0	12
Localised infection		
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)
occurrences (all)	0	4
Lower respiratory tract infection		
subjects affected / exposed	1 / 21 (4.76%)	9 / 292 (3.08%)
occurrences (all)	1	12

Oral herpes		
subjects affected / exposed	1 / 21 (4.76%)	13 / 292 (4.45%)
occurrences (all)	1	19
Nasopharyngitis		
subjects affected / exposed	2 / 21 (9.52%)	18 / 292 (6.16%)
occurrences (all)	4	28
Orchitis		
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Otitis media		
subjects affected / exposed	0 / 21 (0.00%)	3 / 292 (1.03%)
occurrences (all)	0	3
Pharyngitis		
subjects affected / exposed	1 / 21 (4.76%)	2 / 292 (0.68%)
occurrences (all)	1	2
Pneumonia		
subjects affected / exposed	0 / 21 (0.00%)	21 / 292 (7.19%)
occurrences (all)	0	24
Respiratory tract infection		
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)
occurrences (all)	0	7
Rhinitis		
subjects affected / exposed	2 / 21 (9.52%)	7 / 292 (2.40%)
occurrences (all)	2	7
Septic shock		
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Sinusitis		
subjects affected / exposed	0 / 21 (0.00%)	16 / 292 (5.48%)
occurrences (all)	0	21
Staphylococcal infection		
subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Skin infection		
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)
occurrences (all)	0	6

Tooth infection subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	8 / 292 (2.74%) 9	
Urinary tract infection subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 6	39 / 292 (13.36%) 68	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 3	43 / 292 (14.73%) 72	
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 292 (0.00%) 0	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 4	59 / 292 (20.21%) 70	
Dehydration subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	5 / 292 (1.71%) 5	
Folate deficiency subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	5 / 292 (1.71%) 5	
Gout subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	9 / 292 (3.08%) 9	
Hypercholesterolaemia subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	5 / 292 (1.71%) 5	
Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2	15 / 292 (5.14%) 18	
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1	22 / 292 (7.53%) 49	
Hypermagnesaemia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0
Hyperphosphataemia		
subjects affected / exposed	0 / 21 (0.00%)	4 / 292 (1.37%)
occurrences (all)	0	9
Hypertriglyceridaemia		
subjects affected / exposed	0 / 21 (0.00%)	6 / 292 (2.05%)
occurrences (all)	0	13
Hyperuricaemia		
subjects affected / exposed	0 / 21 (0.00%)	27 / 292 (9.25%)
occurrences (all)	0	36
Hypokalaemia		
subjects affected / exposed	0 / 21 (0.00%)	12 / 292 (4.11%)
occurrences (all)	0	12
Hypocalcaemia		
subjects affected / exposed	0 / 21 (0.00%)	11 / 292 (3.77%)
occurrences (all)	0	14
Hypomagnesaemia		
subjects affected / exposed	0 / 21 (0.00%)	10 / 292 (3.42%)
occurrences (all)	0	15
Hypophosphataemia		
subjects affected / exposed	1 / 21 (4.76%)	3 / 292 (1.03%)
occurrences (all)	2	6
Hyponatraemia		
subjects affected / exposed	1 / 21 (4.76%)	20 / 292 (6.85%)
occurrences (all)	1	25
Iron overload		
subjects affected / exposed	0 / 21 (0.00%)	10 / 292 (3.42%)
occurrences (all)	0	10
Tumour lysis syndrome		
subjects affected / exposed	0 / 21 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	1
Type 2 diabetes mellitus		
subjects affected / exposed	2 / 21 (9.52%)	3 / 292 (1.03%)
occurrences (all)	2	3
Vitamin D deficiency		

subjects affected / exposed	1 / 21 (4.76%)	7 / 292 (2.40%)	
occurrences (all)	1	7	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 January 2018	Amendment 6: A Phase 2 component was added in place of the dose expansion phase of the study to evaluate the efficacy of pelabresib with or without ruxolitinib in patients with myelofibrosis (MF). The dose escalation component of the study was subsequently referred to as Phase 1. As of Amendment 6, Phase 1 was complete, and all new patients were enrolled in Phase 2.
07 September 2018	Amendment 7: * The two arms were stratified into transfusion-dependent (TD) and non-transfusion-dependent (non-TD) cohorts. Arm 1 (Prior Janus kinase inhibitor [JAKi] Monotherapy Arm; previously the Monotherapy Arm) was stratified into Cohort 1A (TD) and Cohort 1B (non-TD), and Arm 2 (Prior JAKi Combination Arm; previously the Combination Arm) was stratified into Cohort 2A (TD) and Cohort 2B (non-TD). * A new combination arm was added for patients with myelofibrosis (MF) who had not previously been treated with a JAKi (i.e., JAKi-naïve). This arm was designated Arm 3: JAKi-Naïve Combination Arm. * Key features related to these changes were expanded, including specification of eligibility criteria and primary endpoints for TD versus non-TD cohorts. * Guidelines for dose adjustments and rules for concomitant treatments were updated.
23 September 2019	Amendment 8: * The new starting doses of pelabresib and ruxolitinib were confirmed based on the recommendations of the Safety Review Committee. * Specific instructions for dose modifications due to toxicity were added, replacing the previous approach of following institutional practice. * The number of patients in the JAKi-Naïve Combination Arm 3 was increased to more fully evaluate the efficacy and safety of pelabresib in combination with ruxolitinib. * The anemia component of the required diagnosis of myelofibrosis (MF) for study entry was removed to ensure that study patients were representative of the intended patient population. * The methodology for determining spleen volume at screening was changed to ensure more consistent assessments of baseline disease and response to study drug. * A lower-dose pelabresib and ruxolitinib combination was added for a subset of patients in the JAKi-Naïve Combination Arm 3 to study the safety and efficacy of a reduced pelabresib dose. * The Dynamic International Prognostic Scoring System (DIPSS) category in Arms 1–3 was changed to intermediate-2 or higher.
14 April 2020	Amendment 9: * Adverse event (AE) prophylaxis was added. * Guidelines for managing infection, concomitant use of systemic corticosteroids, and hyperkalemia were added. * Recommendations for the dose regimen and dose modifications in Arm 3 were updated. * The AE relatedness criteria were revised to provide more specificity in possible responses.
25 September 2020	Amendment 10: * A study arm (Arm 4) was added to enroll high-risk essential thrombocythemia (ET) patients who were resistant or intolerant to hydroxyurea (HU). * Cohort 1B was expanded to enroll up to 50 patients. * Arm 3 was reduced to a maximum of 81 patients. * Guidance for dose reductions and modifications for pelabresib and ruxolitinib was revised and clarified. * Guidelines for handling unforeseen circumstances were added to address potential risks to patients.
16 September 2022	Amendment 11: * An exploratory objective was added to evaluate overall survival in Arm 3. * Acute respiratory distress syndrome (ARDS), considered a respiratory distress syndrome (RDS) event, was added as an adverse event of special interest (AESI). * Guidance regarding COVID-19 and contraception was updated. * Assessments of acute myeloid leukemia (AML) transformation, new anti-cancer therapy, and survival follow-up were added to the schedule of events.

27 November 2023	Amendment 12: * Guidance on contraception use during the study was updated. * Confirmation was added that no further pharmacokinetic (PK) samples or allele burden blood samples would be collected.
23 February 2024	Amendment 13: * A benefit-risk assessment was added. * Dose modification guidance and withdrawal criteria for increases in peripheral blood blasts were added. * Accelerated phase (AP) and transformation to blast phase (BP) were added as adverse events of special interest (AESIs). * Adverse event (AE) reporting guidance related to AESIs of AP and transformation to BP was updated.

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please go to <https://www.novctrd.com/#/> for complete trial results

Notes: